<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
    <title>Bariatric Alt: surgery, endoscopy or medication, compared on evidence</title>
    <subtitle>Alternatives to bariatric surgery compared on the published evidence: GLP-1 drugs against sleeve and bypass, endoscopic sleeve gastroplasty, gastric balloons, costs, durability and who still needs the operation.</subtitle>
    <link rel="self" type="application/atom+xml" href="https://bariatricalt.com/atom.xml"/>
    <link rel="alternate" type="text/html" href="https://bariatricalt.com"/>
    <generator uri="https://www.getzola.org/">Zola</generator>
    <updated>2026-11-01T00:00:00+00:00</updated>
    <id>https://bariatricalt.com/atom.xml</id>
    <entry xml:lang="en">
        <title>Alternatives to Bariatric Surgery, Ranked by Evidence</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/alternatives-to-bariatric-surgery/"/>
        <id>https://bariatricalt.com/alternatives-to-bariatric-surgery/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/alternatives-to-bariatric-surgery/">&lt;p&gt;One thing that happens when a field gets a powerful new tool is that every paper about the old tool grows a sentence explaining where the new tool fits, and that sentence tries to fit it everywhere at once. Bariatric surgery got its new tool in GLP-1 drugs, and a focused review titled “Long-Term Effects of Bariatric Surgery on Type 2 Diabetes” wrote the sentence: GLP-1 receptor agonists and dual GIP&#x2F;GLP-1 therapies “may serve as alternatives, bridges, or postoperative adjuncts to bariatric surgery for T2DM, though post-surgical evidence remains limited.” This post reads that sentence the way you would read a contract, clause by clause, because in some sense it is the whole field in 25 words.&lt;&#x2F;p&gt;
&lt;p&gt;First, the plain answer. The alternatives to bariatric surgery with real comparative evidence behind them are GLP-1-type drugs (semaglutide and tirzepatide), endoscopic sleeve gastroplasty (ESG), and intragastric balloons. Where those alternatives have been measured against surgery, surgery wins: a 2026 systematic review found it beat incretin drugs on every primary outcome it measured, and a network meta-analysis of randomized trials found ESG beat the balloons at 12 months.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-alternatives-to-bariatric-surgery-actually-are-by-evidence&quot;&gt;What the alternatives to bariatric surgery actually are, by evidence&lt;&#x2F;h2&gt;
&lt;p&gt;Ranked by how much evidence stands behind them, the list goes like this. Surgery itself has the deepest record, including data at 10 years and beyond. The drugs have a head-to-head systematic review against surgery. ESG and balloons have randomized trials against each other, ranked at 12 months. Combinations (a drug plus an endoscopic procedure, a drug after surgery) have the thinnest evidence, mostly reviews and trials still reporting.&lt;&#x2F;p&gt;
&lt;p&gt;That is the overview. The rest is the sentence, because the sentence explains why the overview looks the way it does. (Individual procedures get their own articles elsewhere on this site.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-may-serve-commits-anyone-to&quot;&gt;What “may serve” commits anyone to&lt;&#x2F;h2&gt;
&lt;p&gt;In a contract, “may” grants permission and imposes no obligation. A landlord who “may” fix the roof has promised nothing about the roof. So the first clause says GLP-1 drugs are permitted to serve as alternatives to surgery. It does not say they do.&lt;&#x2F;p&gt;
&lt;p&gt;Then comes the list of roles: “alternatives, bridges, or postoperative adjuncts.” These are three different jobs. An alternative is instead of surgery. A bridge comes before it. An adjunct comes after. It is a bit like a friend who offers to drive you to the airport, or to the train station that goes to the airport, or to pick you up when you land, and who has so far only done the third one twice. The drug in this sentence is a utility infielder, listed at short, second and third, with no starting position.&lt;&#x2F;p&gt;
&lt;p&gt;The sexy word in the sentence is “alternatives.” The word doing the work is “limited.”&lt;&#x2F;p&gt;
&lt;p&gt;Also, “for T2DM.” Read literally, the whole sentence is scoped to type 2 diabetes, not to weight. (Diabetes remission has its own article here.) And the same review says nearly the same thing twice, once as “adjuncts to bariatric surgery” and once as adjuncts “alongside bariatric surgery.” “To” implies the drug is attached to the operation. “Alongside” implies they merely share a room. I don’t know which one the authors meant. Possibly both, lol.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-strong-the-evidence-for-drugs-as-an-alternative-is&quot;&gt;How strong the evidence for drugs as an alternative is&lt;&#x2F;h2&gt;
&lt;p&gt;The “alternatives” clause has the most evidence behind it, and that evidence mostly says no. A 2026 PRISMA-compliant systematic review of incretin-based therapies versus bariatric and metabolic surgery found 14 studies (8 randomized trials, 6 matched cohorts, 25,566 people) published between January 2014 and April 2026. Its conclusion, in its own words, was that surgery “demonstrated superiority over incretin-based therapies across all five primary outcome domains”: diabetes remission, weight reduction, heart attacks and deaths, fatty liver resolution, and quality of life.&lt;&#x2F;p&gt;
&lt;p&gt;The numbers are not close. Surgery achieved diabetes remission in 23 to 70 percent of patients, compared with 0 percent on incretin drugs. Five-year weight loss was 25 to 32 percent after surgery against 14.9 to 20.9 percent on semaglutide or tirzepatide. The pooled relative risk of major cardiovascular events for surgery versus GLP-1 drugs was 0.48. (Six of the 14 studies were matched cohorts rather than randomized trials, which is worth holding in mind with any number that confident.) The facts here also do not say how remission was counted for patients still taking a diabetes drug, which matters a great deal for a number like zero.&lt;&#x2F;p&gt;
&lt;p&gt;Surgery is not one thing, either. At 10 years, average total weight loss ranges from 24.4 percent for the sleeve to roughly 40 percent for the duodenal switch. And diabetes “remission” after surgery leaks: in one cohort of 2,197 patients with diabetes, 93.6 percent got at least 90 days off diabetes medication, and 42.9 percent of those later went back on it, with a median of about a year before they did. Bypass patients were less likely to restart than sleeve patients (hazard ratio 0.778).&lt;&#x2F;p&gt;
&lt;p&gt;The bridge clause has a little evidence. One single-center retrospective study found patients on GLP-1 drugs before surgery lost a median 9.0 kg beforehand, against 5.0 kg with no drug. That is a bridge that holds weight. It is also one study.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-endoscopic-sleeves-and-balloons-rank&quot;&gt;Where endoscopic sleeves and balloons rank&lt;&#x2F;h2&gt;
&lt;p&gt;The endoscopic options are not in the sentence at all, which is its own literal reading: they are the alternatives that do not even get a “may.” Their evidence lives elsewhere. A network meta-analysis of randomized trials found ESG “ranked highest for weight loss efficacy at 12-month follow-up,” with a P-score of 0.899, ahead of the Spatz3 and Orbera balloons.&lt;&#x2F;p&gt;
&lt;p&gt;A P-score is a rank, not a size. It tells you ESG came first, not by how much, and 12 months is a short contract term for a disease measured in decades. How ESG or balloons compare with surgery over 10 years is, on these facts, not settled.&lt;&#x2F;p&gt;
&lt;p&gt;There is one interesting crossover. A scoring tool built to predict diabetes remission after surgery (the IMS score) also predicted it after ESG: 60 percent remission in mild cases, 45.5 percent in moderate, 0 percent in severe. The same predictors (shorter diabetes duration, lower starting HbA1c, preserved beta-cell function) show up for surgery and for GLP-1 drugs too. Which suggests, in some sense, that the patient is a bigger variable than the procedure.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-post-surgical-evidence-remains-limited-leaves-open&quot;&gt;What “post-surgical evidence remains limited” leaves open&lt;&#x2F;h2&gt;
&lt;p&gt;The adjunct clause is where the sentence admits it is mostly a promise. The BARI-STEP trial is testing semaglutide 2.4 mg once weekly against placebo in people with “suboptimal clinical response” after surgery, defined as less than 20 percent weight loss. The facts here describe its design, not its results. Limited indeed.&lt;&#x2F;p&gt;
&lt;p&gt;A systematic review found that adding liraglutide to endoscopic therapy produced weight loss comparable to surgery’s net weight loss, meaning its lowest weight minus what was regained. Read literally, the comparison is to surgery after some of it wore off. It’s fine. It is just a specific benchmark.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented patient, purely hypothetical. She starts a GLP-1 drug as a bridge, loses weight, has a sleeve, regains some, goes back on the drug as an adjunct, has an endoscopic procedure on top, and continues the drug alongside that. At every step the drug was serving in one of its three permitted roles. By the end it has been her alternative, her bridge, and her adjunct, and the review’s sentence covers all of it, presumably without having predicted any of it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-everyone-writes-the-sentence-this-way&quot;&gt;Why everyone writes the sentence this way&lt;&#x2F;h2&gt;
&lt;p&gt;Everyone involved is behaving sensibly. Review authors hedge because the post-surgical trials have not reported, and “may” is the honest word for that. Surgeons point to the head-to-head data because it favors them. Patients want the option with the fewest incisions that still works, which is a reasonable thing to want. And the drug’s real appeal is that it is willing to partner with almost any procedure, which is a commercially attractive quality in a product.&lt;&#x2F;p&gt;
&lt;p&gt;I assume the conversation in the clinic sounds something like: “So this can be instead of the operation, or before it, or after it, and we’ll see which.” I mean, that is accurate. It is just three answers.&lt;&#x2F;p&gt;
&lt;p&gt;Read clause by clause, then, the sentence says the drug may be an alternative to surgery, which the best head-to-head evidence says it mostly isn’t yet, or a bridge, which one study supports, or an adjunct, which trials are still testing, etc. Read the contract all the way to the end and the best-documented alternative to bariatric surgery, for the 5 to 8 percent of patients whose first operation does not work, is a second bariatric surgery. So the sentence can be kept word for word with a new subject: surgery may serve as an alternative, bridge, or postoperative adjunct to surgery, and of all its versions that is the one the evidence covers best.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Bariatric Surgery Cost vs a Lifetime of Medication</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/bariatric-surgery-cost/"/>
        <id>https://bariatricalt.com/bariatric-surgery-cost/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/bariatric-surgery-cost/">&lt;p&gt;A group of researchers took the data from MERIT, a randomized trial of endoscopic sleeve gastroplasty, ran it through the modeled books of an American commercial health insurer, and came out with a price: $23,432 for each quality-adjusted life year the procedure buys over five years. That is not the price of the procedure. It is the price of a result, which is a stranger and more useful thing. It is also the only dollar figure in the research behind this article.&lt;&#x2F;p&gt;
&lt;p&gt;So, plainly: if you searched for bariatric surgery cost hoping for a sticker price on a sleeve or a bypass, the studies collected here do not give one, and they do not give a monthly price for GLP-1 drugs either. What they give is the shape of the bill. Surgery is mostly paid once, up front, with a tail of later costs that is longer than the word “one-time” suggests. Medication is paid for as long as it is taken, and the best head-to-head evidence here found that for type 2 diabetes the drugs produced no remissions at all, which means the bill keeps arriving.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-one-sentence-with-a-dollar-sign-in-it&quot;&gt;The one sentence with a dollar sign in it&lt;&#x2F;h2&gt;
&lt;p&gt;The cost-effectiveness analysis built on the MERIT trial summarizes itself this way: “ESG dominated lifestyle modification alone over longer time horizons and had an ICUR of $23,432&#x2F;QALY over 5 years from a US commercial payer perspective.” It is a dense sentence. Let’s read it like a contract, one clause at a time, because every clause is doing work.&lt;&#x2F;p&gt;
&lt;p&gt;“ESG.” Endoscopic sleeve gastroplasty, the stomach-narrowing procedure done through a scope rather than through incisions (it has its own article on this site, so I will leave the stitching to that one). Note what it is not. It is not the surgical sleeve, and it is not a bypass.&lt;&#x2F;p&gt;
&lt;p&gt;“Dominated lifestyle modification alone.” In health economics, dominated is a term of art. One treatment dominates another when it is both cheaper and better. That is the best possible verdict, and it is delivered here in the flattest possible language. Read cold, “dominated lifestyle modification alone over longer time horizons” sounds like something that happened late at a conference hotel. It is in fact a statement about a spreadsheet.&lt;&#x2F;p&gt;
&lt;p&gt;“Over longer time horizons.” This is the clause doing the most work. The domination happens later. Over the short run the procedure costs more than diet-and-exercise counseling, because you pay for the procedure on day one and the health shows up gradually. Stretch the model out far enough and the avoided costs of obesity catch up and pass the up-front bill. (You and I both know that “longer time horizons” is where most investment pitches go to become true.)&lt;&#x2F;p&gt;
&lt;p&gt;“An ICUR of $23,432&#x2F;QALY.” An incremental cost-utility ratio: the extra dollars spent, divided by the extra quality-adjusted life years gained, compared with the alternative. It is the price of the increment. If the alternative were free and useless the ratio would look one way; against a cheaper, weaker comparator it looks another.&lt;&#x2F;p&gt;
&lt;p&gt;“Over 5 years.” The window. Five years is long enough for some benefit and short enough that the up-front cost still dominates (in the ordinary sense of the word). Change the window and the number changes. That is not a flaw. It is sort of the whole point of stating the window.&lt;&#x2F;p&gt;
&lt;p&gt;“From a US commercial payer perspective.” Whose money. Not the patient’s out-of-pocket money, not society’s, not an employer’s productivity. A commercial insurer’s.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-bariatric-surgery-costs-once-you-read-the-comparator&quot;&gt;What bariatric surgery costs once you read the comparator&lt;&#x2F;h2&gt;
&lt;p&gt;Now the part the sentence leaves to its title. The comparison is ESG “versus lifestyle modification alone,” which means the model sets the procedure against counseling, and the sleeve, the bypass, semaglutide and tirzepatide are all absent from it.&lt;&#x2F;p&gt;
&lt;p&gt;So the one cost-effectiveness study here answers a question adjacent to the one people actually ask. Whether surgery beats a lifetime of medication on cost is not settled by these facts. Nobody in this pile ran that model.&lt;&#x2F;p&gt;
&lt;p&gt;The perspective clause matters more than it looks, and here is a scenario to show why. It is made up. Imagine a woman whose employer insurance changes every three years. Insurer A pays for her procedure in year one. The savings arrive in years four through twenty. Insurer A sees none of them. Insurer B inherits a healthier member for free (a gift it will book as its own good underwriting). Insurer C inherits her a little older and, by the model’s logic, a little cheaper still. Push it far enough and the most profitable strategy for every individual insurer is to wait for the previous one to pay, until the whole country is a game of hot potato in which the potato is a stomach. That is an exaggeration. The point is that a five-year commercial-payer window is the honest window for an insurer that might only have you for five years.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-one-time-surgery-keeps-sending-bills&quot;&gt;Why one-time surgery keeps sending bills&lt;&#x2F;h2&gt;
&lt;p&gt;The appeal of surgery as a financial object is that it looks like a purchase rather than a subscription. The evidence says it is mostly a purchase, with an asterisk.&lt;&#x2F;p&gt;
&lt;p&gt;Take diabetes medication. A retrospective cohort study using electronic health records followed 8,012 patients who had bariatric surgery between 2013 and 2026, of whom 2,197 had type 2 diabetes beforehand. After surgery, 2,056 of them (93.6%) went at least 90 days without diabetes drugs. Great (this is where a cost model would very much like to stop). Then 882 of those people, 42.9%, went back on medication, at a median of 1.04 years after becoming eligible to be counted.&lt;&#x2F;p&gt;
&lt;p&gt;The study’s title says baseline severity is the dominant predictor, and the numbers agree. Preoperative insulin use carried a hazard ratio of 1.627 for going back on drugs; longer diabetes duration carried 1.219 per standard deviation. Age, on the other hand, was not independently associated with re-initiation. And bypass beat the sleeve here, with a hazard ratio of 0.778 for restarting medication.&lt;&#x2F;p&gt;
&lt;p&gt;A review by Ciesielska in Clinical Diabetology puts the general relapse range less tidily: diabetes relapse after surgery runs “from approximately 10% to over 60%.” That is a wide range. For a cost model, it is the difference between a purchase and a purchase plus a prescription.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the operation itself. A meta-analysis on revisional procedures reports that 5 to 8% of primary bariatric procedures produce an inadequate response that requires revisional surgery. So some fraction of one-time payments become two-time payments. Anyway, the asterisk is real but it is an asterisk, not the headline.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-medication-bill-works-like-a-subscription&quot;&gt;Why the medication bill works like a subscription&lt;&#x2F;h2&gt;
&lt;p&gt;The drug side of the ledger is simpler to describe and harder to price. A 2026 systematic review comparing incretin-based therapies with surgery pooled 14 studies (8 randomized trials and 6 matched cohorts, 25,566 people) and reported that surgery “demonstrated superiority over incretin-based therapies across all five primary outcome domains.” Diabetes remission was 23 to 70% with surgery and 0% with the drugs. Five-year weight loss was 25 to 32% with surgery versus 14.9 to 20.9% with semaglutide or tirzepatide. Major cardiovascular events carried a pooled relative risk of 0.48 for surgery.&lt;&#x2F;p&gt;
&lt;p&gt;That review measured outcomes, not dollars. To be fair to the drugs, a 0% remission rate is not quite the indictment it sounds like; a remission is, by definition, a state off treatment, and a drug that works only while you take it is a streaming subscription, not a DVD you own. The show is good while you pay. The cost question is how many years you watch.&lt;&#x2F;p&gt;
&lt;p&gt;And the categories blur. The BARI-STEP trial is testing semaglutide 2.4 mg once weekly in people whose surgery produced less than 20% weight loss. In those people the choice is not purchase or subscription. It is both, stacked.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-is-being-sensible-and-what-is-not-settled&quot;&gt;Who is being sensible, and what is not settled&lt;&#x2F;h2&gt;
&lt;p&gt;Everyone here is acting reasonably from where they sit. The insurer prices a five-year window because it might hold a member for five years. The surgeon thinks in single interventions because that is the unit of her work. The patient who would rather take a weekly injection than have an operation is weighing things no QALY quite captures. The trialists compared ESG with lifestyle modification, presumably because that is a comparator you can actually randomize against.&lt;&#x2F;p&gt;
&lt;p&gt;I can picture the actuary’s meeting. “Great result, love it. What’s the horizon on that?” It is the correct question. It is always the correct question, which is why I write about stomach operations and keep ending up reading footnotes about discount windows.&lt;&#x2F;p&gt;
&lt;p&gt;There are two ways to read the absence of a surgery-versus-drugs cost study. One is that the drugs are newer and the long data simply is not in yet, and someone will run the model when it is. The other is that nobody has a strong incentive to run it, because the party that pays for the operation and the party that would pay for decades of medication are often not the same party at the same time. I guess both could be true. The facts here do not say which.&lt;&#x2F;p&gt;
&lt;p&gt;What they do say is that the up-front stuff and the ongoing stuff are different kinds of money, and that the comparison depends on the window. The operation is a purchase. The drug is rent, and nobody here has priced the rent.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Bariatric Surgery Twenty Years Later: The Swedish Obese Subjects Study</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/bariatric-surgery-long-term-results/"/>
        <id>https://bariatricalt.com/bariatric-surgery-long-term-results/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/bariatric-surgery-long-term-results/">&lt;p&gt;Here is how a gastric bypass ages. In a Geisinger study of people who had Roux-en-Y gastric bypass and were followed for up to 20 years, average weight loss peaked at 31.8% of body weight at 18 months, then drifted back and settled at 23% between year 10 and year 20. It stopped moving. That is basically the whole story, and the rest of this article is the long version of it.&lt;&#x2F;p&gt;
&lt;p&gt;If you want to know what bariatric surgery long term actually does, the plain answer from the studies that follow people for a decade or more is this. Most of the weight loss holds at a lower level than the peak. Diabetes often stays in remission, depending a lot on how bad it was going in and which operation was done. A meaningful share of patients need a second operation. A few slow problems, like bone health, show up years later. The Swedish Obese Subjects study is the famous name in this field, and its own numbers are not among the sources this article is built on. So I won’t quote them. What follows comes from the other long-term cohorts that are.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-dumb-version-weigh-people-for-twenty-years&quot;&gt;The dumb version: weigh people for twenty years&lt;&#x2F;h2&gt;
&lt;p&gt;The simplest way to judge an operation is to weigh people before it, weigh them after it, and keep weighing them until the research grant runs out. Geisinger did roughly this. Its patients started at a mean age of 46 and a mean BMI of 47.9, and the follow-up is unusually good: 68% of patients (1,388 people) had 10 or more years of data, and 48% (987 people) had more than 15. In a field where people move, change insurance and stop answering the phone, that is a lot of phone calls.&lt;&#x2F;p&gt;
&lt;p&gt;I assume some of those calls went like this (invented, but plausible): “Hi, this is the bypass study. You may remember us from your surgery. Could you step on a scale and tell us what it says?” Do that a thousand times a year for two decades and you get a curve. It goes down hard, bottoms out at 18 months, comes back up a bit, and flattens.&lt;&#x2F;p&gt;
&lt;p&gt;Other operations land in the same neighborhood. A review of results at 10 years and beyond found weighted mean total weight loss ranging from 24.4% for sleeve gastrectomy to about 40% for the duodenal switch. A separate review put the sleeve at 25 to 30% total weight loss at two to five years. So the sleeve also gives some back. Everything gives some back.&lt;&#x2F;p&gt;
&lt;p&gt;The trap in the dumb version is the peak. Judging an operation by its 18-month number is like judging a basketball player by his best season and assuming he plays that way at 39. (Hospitals that only report first-year results are not lying, exactly. They are just leaving the room early.) Pushed to its limit, this produces a made-up clinic whose entire follow-up schedule is one visit at month 18, forever, so that every patient it has ever treated is permanently at peak weight loss, and its brochure shows a 31.8% line extending to the heat death of the universe. Nobody runs that clinic. The long-term studies exist so that nobody can.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sophisticated-version-count-the-deaths-the-diabetes-and-the-second-operations&quot;&gt;The sophisticated version: count the deaths, the diabetes and the second operations&lt;&#x2F;h2&gt;
&lt;p&gt;The sophisticated version says weight is a proxy. What we actually care about is whether people live longer, whether their diabetes goes away and stays away, and how many times they end up back in an operating room. This is a much harder set of questions, and it takes much longer to answer.&lt;&#x2F;p&gt;
&lt;p&gt;Start with deaths. In the Geisinger cohort, the overall 15-year mortality rate was 13.3%, rising to 37.4% among patients with diabetes who were older than 60. That reads like a verdict on the operation. It is actually a verdict on something else: these were people who walked in at 46 with a BMI near 48, often with diabetes, and then lived for 15 more years. The American Society for Metabolic and Bariatric Surgery, describing the study, said “no deaths” were “related to the surgical procedure itself.” Without a matched group of similar people who did not have surgery, the 13.3% cannot tell you on its own whether the surgery saved lives. That comparison is the thing a study like Swedish Obese Subjects was designed to make, and it is not settled by the facts here. A 2026 systematic review comparing surgery with semaglutide and tirzepatide did report surgery ahead across five outcome groups, one of which was major cardiac events and all-cause mortality. For context, a six-year cohort of 1,377 endoscopic sleeve patients reported no mortality, which is a different procedure measured over a shorter window.&lt;&#x2F;p&gt;
&lt;p&gt;Then diabetes. A Mayo Clinic study found 75% of bypass patients still in diabetes remission at five years even after regaining weight, compared with 34.8% of sleeve patients, and the odds of the diabetes coming back were 5.5 times higher after the sleeve. Geisinger found diabetes was much more likely to persist in people who were on insulin before surgery. A review in Clinical Diabetology summed this up as long-term results that “depend largely on disease severity and residual β-cell function.” In plain words, the operation works best on a pancreas that still has some fight left. The DIABETCIR trial, which randomized 45 patients across three operations, found that a shorter history of diabetes, more weight lost in year one, and an early rise in GLP-1 hormone all predicted remission at ten years, regardless of technique. (The body makes its own GLP-1. An entire drug industry now exists to supply more of it.)&lt;&#x2F;p&gt;
&lt;p&gt;I mean, this is all sort of thing that makes sense in hindsight. The more damage was done before the operation, the less the operation can undo.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;durability-or-how-often-the-first-operation-is-the-last-one&quot;&gt;Durability, or how often the first operation is the last one&lt;&#x2F;h2&gt;
&lt;p&gt;Here the sophisticated version gets uncomfortable. In the Polish BARI-10-POL study of 485 patients operated on between 2008 and 2014, revisional surgery was needed in 23.9% of patients over ten years, including 24.3% of sleeve patients. Among adjustable gastric band patients, the revision rate was not high. Correction: it was 100%. Every single one. That is not a complication rate so much as a scheduling assumption.&lt;&#x2F;p&gt;
&lt;p&gt;The American LABS study, which followed patients at 10 hospitals from 2006 to 2009 surgery dates through early 2015, saw the same pattern from another angle: 14 reoperations among bypass patients versus 160 among band patients over seven years. The band did not age well. (Its history gets its own article on this site, so I’ll leave it there.)&lt;&#x2F;p&gt;
&lt;p&gt;Revisions are not free. A review in Frontiers put it this way: surgical revision and conversion “are associated with higher morbidity and mortality compared to the primary surgical intervention.” Pouch resizing after bypass weight regain stabilized BMI from 39 to 35 at five years but carried a 10.4% serious complication rate. When a sleeve is converted to a one-anastomosis bypass, leakage was the most common major complication. So the line between “I had weight-loss surgery” and “I have an ongoing arrangement with a surgical department” is, for a quarter of patients, a little blurry.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-late-complications-that-take-a-decade-to-show-up&quot;&gt;The late complications that take a decade to show up&lt;&#x2F;h2&gt;
&lt;p&gt;Some costs only appear if you wait. A prospective study of 60 patients (20 bypass, 20 one-anastomosis bypass, 20 sleeve) checked bone density at a mean of 10.1 years. Lumbar spine density showed no significant change, which is fine. But the estimated 10-year risk of major osteoporotic and hip fractures was elevated after all three operations. Sixty people is small. It is a signal, not a settled number, and nobody knows its size precisely from this.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the skin. People who lose a great deal of weight often have surgery to remove what is left over, and one review found major complications after abdominoplasty in 22.0% of bariatric patients versus 8.5% of diet-and-exercise patients. After adjusting for BMI, the amount of tissue removed and diabetes, the difference was no longer significant. Bypass patients specifically had a 39.1% major complication rate, in a subgroup of 23 people. So, in some sense, the surgery’s late complications include the complications of its own success, lol, which is a strange sentence to write about a hospital procedure.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-two-versions-end-up&quot;&gt;Where the two versions end up&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version weighs people and concludes that the operation keeps about a quarter of their weight off for twenty years. The sophisticated version counts deaths, remissions, fractures, leaks and revisions, adjusts for baseline disease, argues about comparison groups and then concludes, after many more pages, that the operation keeps working at a lower level than its peak, works better on earlier disease, and sometimes needs a second operation. I don’t know that the extra pages changed the answer. They changed how confident anyone can be in it. (I write about this from a desk, so my own longitudinal data is mostly rereading abstracts and noticing the follow-up percentages.)&lt;&#x2F;p&gt;
&lt;p&gt;The 2026 review comparing surgery with the newer drugs found five-year weight loss of 25 to 32% after surgery versus 14.9 to 20.9% on semaglutide or tirzepatide. The surgical number there looks a lot like the Geisinger plateau. It took twenty years of phone calls to find it.&lt;&#x2F;p&gt;
&lt;p&gt;The weight goes down, comes back a little, and then stays.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Weight-Loss Surgery and Medication for Teenagers</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/bariatric-surgery-teens/"/>
        <id>https://bariatricalt.com/bariatric-surgery-teens/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/bariatric-surgery-teens/">&lt;p&gt;In a cohort of 2,197 bariatric surgery patients who had type 2 diabetes before their operations, researchers checked whether a patient’s age predicted the diabetes coming back. It did not. What predicted it was how long the patient had already had diabetes. That is an odd thing to hold in your head if you came here wondering about bariatric surgery for teens, because a teenager is basically the person who has had the least time to have anything.&lt;&#x2F;p&gt;
&lt;p&gt;Here is the plain answer, as far as this article’s facts go. The adolescent-specific evidence (the Teen-LABS outcomes, the adolescent GLP-1 drug trials, the professional guidelines on who qualifies and when) is not among the figures this piece is built on, so I am not going to quote numbers for it. What the facts do contain is a lot of adult evidence, on surgery and on drugs, and some of it bears on the question of age in a sideways way. The sideways way is sort of the whole story.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-evidence-here-says-about-bariatric-surgery-for-teens&quot;&gt;What the evidence here says about bariatric surgery for teens&lt;&#x2F;h2&gt;
&lt;p&gt;The cohort above comes from a paper titled “Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re-Initiation Following Bariatric Surgery,” and the title is doing most of the work. Of those 2,197 patients, 2,056 (93.6%) got what the paper calls “a postoperative medication-free interval of at least 90 days.” Translated: after the operation, they went three months without needing diabetes drugs. Then 882 of them, or 42.9%, started taking diabetes medication again, at a median of 1.04 years after they became eligible to be counted.&lt;&#x2F;p&gt;
&lt;p&gt;The things that predicted going back on medication were the things that describe a long, heavy disease history. Higher baseline HbA1c had a hazard ratio of 1.089 per standard deviation. Preoperative insulin use had a hazard ratio of 1.627. Longer diabetes duration had a hazard ratio of 1.219 per standard deviation. And, per the study, “Age was not independently associated with diabetes medication re-initiation after bariatric surgery in Cox model analysis.”&lt;&#x2F;p&gt;
&lt;p&gt;This is an adult cohort. It does not tell you how teenagers do. It tells you that, among adults, the clock that mattered was the disease’s clock, not the birthday clock.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-case-for-operating-earlier-taken-one-step-at-a-time&quot;&gt;The case for operating earlier, taken one step at a time&lt;&#x2F;h2&gt;
&lt;p&gt;Start with a reasonable version. (This patient is invented.) A 50-year-old has had type 2 diabetes for fifteen years and is on insulin. Her doctors propose surgery. The adult data say her odds of staying off medication are worse than average, because she has the two features the cohort flagged: insulin use and a long duration.&lt;&#x2F;p&gt;
&lt;p&gt;I want to sit with that 1.219 for a moment, because it is a strange little number. It is a per-standard-deviation figure (the paper’s unit, not mine, and the facts here do not say how many years one standard deviation of diabetes duration works out to in this cohort). Each step of extra duration multiplies the hazard by roughly a fifth again. It doesn’t plateau. There is no point in the number where it says “and after this, it stops mattering.” It just keeps compounding, quietly, like a credit card nobody opens the statement for.&lt;&#x2F;p&gt;
&lt;p&gt;So the obvious move is to operate on her at 40, after five years of diabetes instead of fifteen. A separate review of diabetes remission says the same direction: “Key predictors of T2DM remission after both bariatric surgery and GLP-1 therapy include shorter diabetes duration, lower baseline HbA1c, reduced treatment burden, and preserved β-cell function.” Shorter is better. Fine. Then at 35, right at diagnosis. Then, logic applied without mercy, the 30-year-old with prediabetes, and then the 25-year-old who has nothing yet but a BMI and a family history, and then the 16-year-old, and then, I don’t know, a promising toddler (lol, no). At the end of this road is a surgeon leaning into a maternity ward saying “hey, congratulations on the baby, we’ve had a cancellation at two o’clock.”&lt;&#x2F;p&gt;
&lt;p&gt;Nobody does that. But the road has a real middle. The fact that people type the search phrase at all tells you the medical world has walked some distance down it, and the question is how far, and on what evidence.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-adult-surgery-numbers-actually-show-over-time&quot;&gt;What the adult surgery numbers actually show over time&lt;&#x2F;h2&gt;
&lt;p&gt;If you are deciding something for a person who has seventy years ahead of them, the number you care about is not the one-year number. It is the long one. The adult long-term numbers in hand look like this. In the LABS study (the adult Longitudinal Assessment of Bariatric Surgery), seven years after gastric bypass, “mean weight loss was 38.2 kg,” which the study says represented 28.4% of baseline weight. Seven years after a gastric band, it was 14.9%. In the Oseberg trial, the sleeve produced 17.2% total weight loss at five years, and bypass beat it by 5.0 percentage points.&lt;&#x2F;p&gt;
&lt;p&gt;A review of very long-term outcomes put weighted mean total weight loss at 10 years at 24.4% for the sleeve, ranging up to roughly 40% for the duodenal switch. Another source says up to half of sleeve patients may require conversion surgery because of insufficient weight loss, weight recurrence, or complications. That last figure is an adult figure over adult time horizons. A teenager has more years in which “up to half” can play out, but that is arithmetic, not data, and the facts here do not say what happens over fifty years. Nobody has fifty-year data on this. (The site has its own pieces on weight regain and on the Swedish long-term study, so I will leave that ground to them.)&lt;&#x2F;p&gt;
&lt;p&gt;There is also the question of why surgery works, which matters because it determines whether earlier is better or just earlier. A review in Clinical Diabetology says “Metabolic improvement after bariatric surgery results from both weight loss-dependent effects and surgery-specific mechanisms that are independent of weight loss.” So part of the effect is plumbing. In some sense that is the case for surgery and the case for caution at once.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-drugs-which-also-have-adult-numbers&quot;&gt;The drugs, which also have adult numbers&lt;&#x2F;h2&gt;
&lt;p&gt;The drug side of the comparison has the same shape: big adult numbers, nothing adolescent in the facts here. In the SURMOUNT-1 trial, tirzepatide 15 mg produced 22.5% mean body weight loss, and 36.2% of that dose group lost at least a quarter of their body weight. A network meta-analysis of 23 randomized trials found tirzepatide at 10 or 15 mg produced 21.3% total weight loss, statistically equivalent to the sleeve’s 21.1%.&lt;&#x2F;p&gt;
&lt;p&gt;Then a 2026 systematic review looked at five-year numbers and found surgery at 25% to 32% versus 14.9% to 20.9% for semaglutide or tirzepatide, with surgery ahead on all five of its primary outcome domains. Short trials favor the drug comparison. Long ones favor the knife.&lt;&#x2F;p&gt;
&lt;p&gt;For a teenager, the drug question is really a duration question. A pill or injection works while you take it; the comparison only gets interesting if you imagine taking it from age 14 onward. I am sure the companies running adolescent trials are motivated entirely by unmet medical need, and it is simply a coincidence that a 14-year-old has more years of refills ahead of her than anyone else in the waiting room. It’s fine. Incentives can point the right way too.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-is-not-settled-which-is-the-teen-part&quot;&gt;What is not settled, which is the teen part&lt;&#x2F;h2&gt;
&lt;p&gt;Look, I write about this for a living, which mostly means reading hazard ratios so other people don’t have to (a service whose value I would not want independently audited). And the honest report is that the specific things a reader searching this phrase wants are the specific things missing here. How teenagers do after surgery over many years: not in these facts. How teenagers do on GLP-1 drugs in trials: not in these facts. What the guidelines say about age, BMI thresholds, or sequencing: not in these facts.&lt;&#x2F;p&gt;
&lt;p&gt;What you can say is narrower. The adult evidence says long disease history predicts worse diabetes outcomes after surgery. It says surgery’s weight loss holds up better at five and ten years than drug trials have so far shown. It says some operations need redoing. Every one of those findings pulls in a different direction when you move it onto a younger body. Not settled, then.&lt;&#x2F;p&gt;
&lt;p&gt;It is a bit like the sports draft logic of taking the 19-year-old for upside: you are buying the future, which is exactly the part with no film on it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-far-along-the-road-the-real-world-already-is&quot;&gt;How far along the road the real world already is&lt;&#x2F;h2&gt;
&lt;p&gt;The escalation went: operate earlier, then earlier, then at diagnosis, then before diagnosis, then on teenagers, then on toddlers. The real world has stopped somewhere past adults and well short of maternity wards, and the evidence that would tell you exactly where it should stop is the evidence this article does not have.&lt;&#x2F;p&gt;
&lt;p&gt;But there is one thing the adult data do say, and it is sort of funny once you see it. Everyone arguing about operating on teenagers is arguing about age. In the one cohort here that checked, age dropped out of the model entirely, and the variable that mattered was the one teenagers have the least of.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Diabetes Remission: Surgery vs GLP-1 Drugs</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/bypass-vs-glp-1-diabetes-remission/"/>
        <id>https://bariatricalt.com/bypass-vs-glp-1-diabetes-remission/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/bypass-vs-glp-1-diabetes-remission/">&lt;p&gt;I spent a good part of this week reading the word “remission” in diabetes papers, and it turns out to mean several different things depending on who is counting. The short answer on bariatric surgery diabetes remission: a large share of people with type 2 diabetes who have the operation end up with near-normal blood sugar without diabetes drugs. Reported rates run from about 23% to over 70%, depending on the operation, the definition and how long anyone waited to check. A review in Clinical Diabetology by Ciesielska and colleagues, published August 12, 2026, says remission rates “exceed 70%, though outcomes vary by follow-up duration and surgical procedure.”&lt;&#x2F;p&gt;
&lt;p&gt;The drugs score much lower. A 2026 head-to-head systematic review of incretin-based therapies (the GLP-1 family and its relatives) against surgery found surgical remission of 23% to 70% and drug remission of 0%. A large observational study of 14,141 people starting GLP-1 drugs found remission in 5.8% to 18.3%, depending on the definition. Some of that gap is biology. Some of it is the word “remission” doing something odd, and that part is worth walking through slowly.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-counts-as-diabetes-remission-starting-small&quot;&gt;What counts as diabetes remission, starting small&lt;&#x2F;h2&gt;
&lt;p&gt;Start with the most reasonable version. Your diabetes is in remission if your blood sugar is no longer diabetic. The usual yardstick is HbA1c, a blood test that averages glucose over a few months. Type 2 diabetes is typically diagnosed at 6.5% or above, so remission could just mean you are now below 6.5%.&lt;&#x2F;p&gt;
&lt;p&gt;That’s fine, but it has an obvious hole. Plenty of people get below 6.5% by taking diabetes drugs, and we presumably don’t want to call a well-controlled patient “in remission” merely because the pills work. So the second version adds a condition: below the threshold and taking no glucose-lowering medication.&lt;&#x2F;p&gt;
&lt;p&gt;That definition has a consequence. For the avoidance of doubt, and with all due solemnity: a person taking a glucose-lowering medication is, for purposes of the off-medication definition, a person taking a glucose-lowering medication. A GLP-1 drug is a glucose-lowering medication. Anyone whose diabetes is controlled by a GLP-1 drug is therefore, by construction, not in remission under this rule, however good their numbers look.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-strict-the-definition-gets-before-it-stops-making-sense&quot;&gt;How strict the definition gets before it stops making sense&lt;&#x2F;h2&gt;
&lt;p&gt;Now escalate. One good blood test off medication might be a fluke, so require the normal number to hold for 90 days. Then, to be safe, for a year. Then for five years, since diabetes can come back and nobody wants to announce a cure and retract it.&lt;&#x2F;p&gt;
&lt;p&gt;Keep going. If remission means the diabetes never returns, the only fully rigorous time to certify it is at the end of the patient’s life. This is like asking whether a pitcher has thrown a no-hitter in the fourth inning. He might. Ask again later (and, by baseball custom, quietly).&lt;&#x2F;p&gt;
&lt;p&gt;The real world is further down this road than you’d hope. One study followed patients who managed at least 90 days off diabetes medication after bariatric surgery. Of those, 882 (42.9%) later went back on medication, at a median of 1.04 years after the clock started. The Ciesielska review puts relapse after surgery at “approximately 10% to over 60%.” So remission is a state you are in until you aren’t, and every number below is a snapshot taken at some arbitrary point on that road.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-surgery-trials-found-when-they-picked-a-number&quot;&gt;What the surgery trials found when they picked a number&lt;&#x2F;h2&gt;
&lt;p&gt;The famous randomized trial here is STAMPEDE, which I am going to name and then set aside, because the trials whose actual numbers I have in front of me are other ones. (My job consists largely of reading the results tables other people worked years to fill in, and then having opinions about the column headers.)&lt;&#x2F;p&gt;
&lt;p&gt;The cleanest illustration of the definition problem is the Oseberg trial in Norway, which randomized people with type 2 diabetes to gastric bypass or sleeve gastrectomy. At 5 years, with remission defined as HbA1c at or below 6.0%, it was 50% for bypass (23 of 46) and 20% for sleeve (9 of 44). Defined as HbA1c below 6.5%, it was 63% versus 30%. Same patients, same operations, different line.&lt;&#x2F;p&gt;
&lt;p&gt;Bypass beat sleeve at every check: by 27 percentage points at 1 year, 67% versus 33% at 3 years, and the figures above at 5 years. The SLEEVEPASS trial in Finland, at 10 years, found 26% for sleeve and 33% for bypass, a difference it called not statistically significant. The small DIABETCIR trial in Spain found remission persisting at 10 years in 8 of 15 bypass patients, 3 of 12 sleeve patients and 4 of 15 patients given a stitched-fold procedure called plication. Those are weirdly small numbers for a ten-year question, but ten-year randomized surgical trials are hard to fill.&lt;&#x2F;p&gt;
&lt;p&gt;The observational data tell the same downhill story. The LABS study found bypass remission of 71.2% at 1 year, sliding to 60.2% at 7 years. A Geisinger Medical Center series of 2,045 bypass patients reported 54% at 3 years and 38% at 15 years. The operation does not undo itself, but the diabetes can come back anyway.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-glp-1-drugs-score-near-zero-on-the-remission-test&quot;&gt;Why GLP-1 drugs score near zero on the remission test&lt;&#x2F;h2&gt;
&lt;p&gt;This is where the escalation pays off. The 2026 systematic review found surgery better than incretin drugs on all five outcomes it compared: remission, weight, major cardiac events and death, fatty liver disease resolution, and quality of life. That is a fairly complete result. On heart attacks and strokes, it reported a pooled relative risk of 0.48 for surgery against GLP-1 drugs, which is to say about half.&lt;&#x2F;p&gt;
&lt;p&gt;But look at the 0% for remission. I assume part of it reflects what the drugs actually do. Part of it is the rule from two sections ago: a drug you are still taking cannot produce off-medication remission. Imagine an endocrinologist saying, “Congratulations, your A1c is 5.8, please continue the medication responsible for the 5.8.” Under the strict definition, that patient is a treatment success and not a remission. Both are true.&lt;&#x2F;p&gt;
&lt;p&gt;The observational GLP-1 study shows the effect directly. Among its 14,141 drug starters, followed for an average of 4 years, remission was 5.8% under strict off-medication criteria and up to 18.3% under more inclusive ones. The authors also found that the people who did reach remission on these drugs had 12% to 16% fewer small-vessel complications. So remission on a drug is rare and seems to matter. Whether a drug-controlled 5.8 should get partial credit is a definitional choice, and the field has not settled it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-stays-in-remission-and-who-goes-back-on-medication&quot;&gt;Who stays in remission and who goes back on medication&lt;&#x2F;h2&gt;
&lt;p&gt;The predictors are the same whichever treatment you look at. A review of surgical and endoscopic options lists them as “shorter diabetes duration, lower baseline HbA1c, reduced treatment burden, and preserved β-cell function” (beta cells being the ones in the pancreas that make insulin). Translated: people with milder, newer diabetes do better.&lt;&#x2F;p&gt;
&lt;p&gt;The medication re-initiation study puts numbers on it. Longer diabetes duration, higher starting HbA1c and preoperative insulin use each predicted going back on drugs, with insulin users at about 1.6 times the hazard. Bypass carried a lower risk of re-initiation than sleeve. Age, once the other things were accounted for, did not predict anything, though the Ciesielska review does list younger age as linked to remission. Different methods, different answers, etc.&lt;&#x2F;p&gt;
&lt;p&gt;The same logic carries over to endoscopic sleeve gastroplasty, which the site covers elsewhere. One study applied a surgical scoring tool, the individualized metabolic surgery score, to ESG patients: remission was 60% for mild diabetes, 45.5% for moderate and 0% for severe. The sickest patients, who presumably need remission most, are the least likely to reach it under any of these treatments. That is not anyone’s fault. It is how the pancreas works.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-drugs-and-the-surgery-meet&quot;&gt;Where the drugs and the surgery meet&lt;&#x2F;h2&gt;
&lt;p&gt;Increasingly the two are not rivals so much as a couple. A focused review describes GLP-1 drugs as possible “alternatives, bridges, or postoperative adjuncts,” which is a polite way of saying they keep hooking up at different stages of the relationship, while noting that the post-surgical evidence “remains limited.”&lt;&#x2F;p&gt;
&lt;p&gt;One single-center study of 193 surgery patients looked at the courtship phase. The 111 who took a GLP-1 drug before the operation lost a median of 9.0 kg beforehand, against 5.0 kg for the 82 who didn’t, and had zero major complications against five. Their diabetes and blood pressure remission at 12 months was similar. So the drug group lost more weight before surgery and ended up with the same remission, in one center, retrospectively, or whatever weight you want to give that.&lt;&#x2F;p&gt;
&lt;p&gt;I suppose the honest summary is that the comparison isn’t quite apples to apples. Surgery is judged on what happens after treatment, because it is a single event. The drugs are judged by a standard they meet only when someone stops taking them.&lt;&#x2F;p&gt;
&lt;p&gt;Surgery wins on remission partly because it is the only treatment nobody can stop taking.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Duodenal Switch and SADI-S: The Strongest Operations</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/duodenal-switch-sadi-s/"/>
        <id>https://bariatricalt.com/duodenal-switch-sadi-s/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/duodenal-switch-sadi-s/">&lt;p&gt;If you want a body to hold on to fewer calories, there are basically two plans. You can make the stomach smaller so less food goes in, which is what the sleeve does, or you can let the food in and then send it past a long stretch of intestine so less of it is kept on the way through. The duodenal switch does both, and its newer cousin SADI-S (single anastomosis duodeno-ileal bypass, which is a lot of syllables for one connection) does roughly the same thing through a single join, as the name says.&lt;&#x2F;p&gt;
&lt;p&gt;On the evidence these are the strongest weight-loss operations around. A review of very long-term outcomes found that at 10 years, weighted mean total weight loss ranged from 24.4% for sleeve gastrectomy to approximately 40% for BPD-DS, and that SADI-S data at 10 years showed 80% excess weight loss “with acceptable complication rates.” The price is malabsorption. The body absorbs less, and it does not get to choose what it absorbs less of. Who should actually get these operations is much less settled than how well they work.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-duodenal-switch-does-in-the-dumb-version&quot;&gt;What a duodenal switch does, in the dumb version&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the mechanism in the plainest words I can manage. You eat food. The food travels down a long tube that pulls useful things out of it. If the food skips most of the tube, less gets pulled out. The official name for this is malabsorption.&lt;&#x2F;p&gt;
&lt;p&gt;The tube works like a toll road with a long row of booths, each collecting a little of what passes. The operation builds an exit ramp that sends traffic around most of the booths and rejoins the road near the end. Same cars, fewer tolls. (Nobody at the Department of Transportation would approve this, which is one advantage of medicine.)&lt;&#x2F;p&gt;
&lt;p&gt;The dumb version also explains why weight stays off. A review in Frontiers on endoscopic fixes for regain said BPD&#x2F;DS is not associated with high rates of weight recurrence because it “significantly induces malabsorption, making it physiologically more complex to regain weight.” That is a careful way of saying the booths are still closed. A separate study of what happens after the conditions come back found RYGB and duodenal switch were associated with lower risks of diabetes and high-cholesterol recurrence compared with sleeve gastrectomy.&lt;&#x2F;p&gt;
&lt;p&gt;Now a hypothetical, clearly made up, to push the dumb version until it breaks. If closing some booths works, close all of them. The patient eats a full dinner, keeps none of it, and becomes a very expensive pipe. This is not a real operation. The reason it is not real is the rest of this article.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-much-weight-the-strongest-operations-take-off&quot;&gt;How much weight the strongest operations take off&lt;&#x2F;h2&gt;
&lt;p&gt;The numbers are large in a way that is a little weird to read next to the sleeve. A network meta-analysis comparing bariatric operations found SADI-S was the most effective for reducing BMI, by a mean difference of 18.06 points (confidence interval 10.81 to 25.31), with heterogeneity of 98.5%. (That last number is the statistician’s way of saying the studies disagreed with each other enormously while all agreeing the answer was big.) The same analysis found the bypass-plus-diversion version (BPD-RYGB) was most effective for absolute weight, at about 41.48 kilograms, and for fat mass, at 31.11 kilograms, with heterogeneity of 0%. For once, everyone agreed.&lt;&#x2F;p&gt;
&lt;p&gt;A different network meta-analysis ranked procedures by how well they improved obesity-related conditions, and SADI ranked highest for diabetes, with a P-score of 0.932. I write about finance, where a ranking with three decimal places usually means someone is about to sell you a fund. Here it is just a meta-analysis. I feel like that is progress.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sophisticated-version-bile-acids-hormones-and-lunch&quot;&gt;The sophisticated version: bile acids, hormones and lunch&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version says food skips the booths. The sophisticated version says something more interesting is going on, and it has a study to prove it. A prospective case-control study compared 37 gastric bypass patients, 31 SADI-S patients and 19 non-obese controls. Its title promises “Nutrient-Stimulated Hormone Responses,” which sounds like a channel you would scroll past quickly in a hotel. It is in fact about what happens to people’s blood after lunch.&lt;&#x2F;p&gt;
&lt;p&gt;The first finding is a bit awkward for the dumb version. A standard bile acid test found no bile acid malabsorption in the SADI-S patients at all. So the malabsorptive operation is not malabsorbing that, at least. Instead, fasting levels of certain conjugated bile acids were higher after SADI-S than after bypass. A gut hormone called FGF19 peaked at 90 minutes after a mixed meal in both groups, and its rise tracked the rise in those bile acids, particularly after SADI-S.&lt;&#x2F;p&gt;
&lt;p&gt;Then the hunger hormone ghrelin went up after bypass but was suppressed after SADI-S. GLP-1 responses were “supraphysiological” after both, meaning the operated gut was producing more of the hormone that the site’s other favorite treatment is named after than a normal gut does. In an exploratory analysis, the bigger the rise in conjugated bile acids, the less weight people regained from their lowest point at 5 years.&lt;&#x2F;p&gt;
&lt;p&gt;There is a related finding from gastric bypass, which also routes food past the duodenum. Patients who regained 100% or more of their surgically lost weight still kept their diabetes in remission in roughly 60% of cases, which the authors read as a weight-independent benefit of the duodenal bypass. So the sophisticated version is: hormones, bile acids, signaling, appetite, etc. It is not just closed booths.&lt;&#x2F;p&gt;
&lt;p&gt;And where does the sophisticated version end up? In that same study, weight loss was greater with SADI-S than bypass at 1 year but not significantly different at 3 and 5 years. The hormones were doing their elaborate thing, and the result was a body that kept less. Which is what the dumb version said.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-malabsorption-costs&quot;&gt;What malabsorption costs&lt;&#x2F;h2&gt;
&lt;p&gt;The bill comes from the same mechanism. The bile acid study reported that “despite routine supplementation, total protein, zinc, copper, and vitamin A&#x2F;RBP and vitamin E&#x2F;cholesterol ratios decreased after both RYGB and SADI-S.” The booths that were collecting calories were also collecting zinc. The exit ramp does not check what kind of car you are.&lt;&#x2F;p&gt;
&lt;p&gt;The consult, presumably, goes something like: “Good news, this is the strongest operation we do. Here is your supplement list. We will be checking your copper.” That is a weird sentence to hear in one breath, but a normal one in this field.&lt;&#x2F;p&gt;
&lt;p&gt;On bones, a long-term study found elevated estimated fracture risk after sleeve, bypass and one-anastomosis bypass. It did not include the duodenal switch or SADI-S, so for the strongest operations that question is not settled by these facts. Which is not reassuring, I suppose, but it is honest.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-these-operations-are-for-as-far-as-anyone-has-settled-it&quot;&gt;Who these operations are for, as far as anyone has settled it&lt;&#x2F;h2&gt;
&lt;p&gt;Partly, they are for people whose first operation was the sleeve. Sleeve gastrectomy is the most performed bariatric procedure worldwide, and in a 10-year multicenter study from Poland called BARI-10-POL, 24.3% of sleeve patients needed a revisional procedure. That is a lot of people looking for a second plan. (Being the most popular first plan has this side effect.)&lt;&#x2F;p&gt;
&lt;p&gt;A meta-analysis of SADI versus one-anastomosis gastric bypass as the second operation found 4 eligible articles with 309 patients total. At 1 year SADI produced more weight loss on both measures. At 2 years excess weight loss no longer differed, though total weight loss stayed higher with SADI. (This is the sports-trade problem: everyone looks like a genius after one season.) Biliary reflux was more common after the one-anastomosis bypass, and seven of its patients developed ulcers against none after SADI, though that gap missed statistical significance with a P value of 0.07. Close, not quite. That’s fine.&lt;&#x2F;p&gt;
&lt;p&gt;For first-time patients, the head-to-head evidence mostly hasn’t arrived. The BYPSADIS randomized trial “will enroll” 450 patients aged 18 to 60 with BMI of 40 to 50 across six hospitals, split evenly between SADI-S and gastric bypass. Another ongoing trial, SADISLEEVE, includes first and revisional operations with no BMI limits and varying limb lengths. So the question of who these are for is, right now, a protocol or whatever. Why it has taken this long for operations ranked first on several measures to get a big randomized trial against the standard is a dumb but real question that the facts here don’t answer.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;same-place-longer-road&quot;&gt;Same place, longer road&lt;&#x2F;h2&gt;
&lt;p&gt;The dumb version of the duodenal switch fits on a napkin: send the food around most of the toll booths, collect fewer tolls. The sophisticated version takes a mixed-meal test, a 90-minute hormone peak, three conjugated bile acids and a suppressed hunger signal to explain itself. Both versions predict lots of weight lost, diabetes that stays away more often, and zinc and protein that go missing alongside the calories.&lt;&#x2F;p&gt;
&lt;p&gt;The exit ramp is fancier than it looked. It is still an exit ramp.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Endoscopic Revision After Bypass: TORe and Friends</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/endoscopic-revision-tore/"/>
        <id>https://bariatricalt.com/endoscopic-revision-tore/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/endoscopic-revision-tore/">&lt;p&gt;Here is a small fact about gastric bypass: the part that does most of the work is a hole. After the operation, food leaves a small stomach pouch through a narrow connection into the intestine, and that connection (surgeons call it the outlet, or the gastrojejunal anastomosis, which is the same hole with more syllables) is supposed to stay narrow. Sometimes it stretches. When it does, food moves through faster, and some patients regain weight.&lt;&#x2F;p&gt;
&lt;p&gt;The tore procedure, which is how most people type it and which the literature writes as TORe, for transoral outlet reduction, is the proposed fix: a doctor goes in through the mouth with an endoscope and sews the stretched outlet smaller again. That is what it is. How much weight it takes back off, and for how long, is a harder question, and the evidence gathered for this article contains no TORe trial result, so on the numbers the honest answer is that it is not settled here. What the evidence does settle is the shape of the problem TORe is meant to solve, and that shape is mostly about who gets paid for which procedure, and when.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-tore-procedure-actually-is&quot;&gt;What the TORe procedure actually is&lt;&#x2F;h2&gt;
&lt;p&gt;Read the name literally. Transoral: through the mouth. Outlet: the exit from the stomach pouch. Reduction: smaller. (Medicine names things the way a contract defines terms, which is to say completely and with no jokes.) It belongs to the same family as endoscopic sleeve gastroplasty, which one narrative review describes as creating a sleeve “through endoscopic suturing to create a tubular gastric sleeve without resection, preserving native anatomy.” Same tools, different target. ESG sews a normal stomach into a tube; TORe sews a bypass outlet back down to size.&lt;&#x2F;p&gt;
&lt;p&gt;The “friends” in the title are the other revisions done this way, for instance resuturing a sleeve gastrectomy that has stretched out over the years. These sit on this site’s ground for revision specifically. Their outcome numbers are not in the source list either. That absence is sort of the point of this article, and we will come back to it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;who-gets-paid-for-the-first-operation-and-what-that-costs-later&quot;&gt;Who gets paid for the first operation, and what that costs later&lt;&#x2F;h2&gt;
&lt;p&gt;Start the chain at the first link. A surgeon performs a primary operation and is paid for it, and the most common one is the sleeve: one comparative study states flatly that “Sleeve gastrectomy is currently the most performed bariatric procedure worldwide.” A long-term review put weighted mean total weight loss at 10 years at 24.4% for the sleeve, rising to about 40% for the duodenal switch. The operation works. It also does not always stay working.&lt;&#x2F;p&gt;
&lt;p&gt;The Polish BARI-10-POL study followed 485 patients, 317 of whom (65.4%) had a sleeve as their first operation. Over 10 years, 23.9% of patients needed a revisional procedure, “most commonly after sleeve gastrectomy (24.3%) and adjustable gastric banding (100%).”&lt;&#x2F;p&gt;
&lt;p&gt;That last figure deserves to be entered into the record with appropriate gravity. A revision rate of 100% means that every member of the relevant class was revised, without exception, over the period of observation, such that a band patient who was not revised would constitute a finding in itself and would presumably merit a paper of her own. The band has its own article on this site. The band is not doing well (this is the polite version).&lt;&#x2F;p&gt;
&lt;p&gt;Second link: a patient regains weight, and the obvious next step is a second operation, which someone is also paid for. Here is how a Frontiers review of endoscopic management puts the trouble with that: surgical revision and conversion “are associated with higher morbidity and mortality compared to the primary surgical intervention.” Translated into a flat sentence: the second operation is more dangerous than the first one. The scar tissue is already there.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-convert-repair-or-medicate-after-a-sleeve-or-bypass&quot;&gt;Why convert, repair, or medicate after a sleeve or bypass&lt;&#x2F;h2&gt;
&lt;p&gt;If a second operation is happening anyway, the question is which one. After a sleeve, the choices on offer include conversion to a Roux-en-Y bypass, to a one-anastomosis gastric bypass (OAGB), or to SADI. A seven-year study of conversions found OAGB produced greater total weight loss and BMI reduction than Roux-en-Y at both 1 and 7 years. A meta-analysis of SADI versus OAGB as revisions found excess weight loss did not differ at two years, but total weight loss stayed higher with SADI. To be fair, these are different patients in different hospitals, and nobody randomized anyone.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the third option, which does not involve an operating room at all. A multicenter retrospective study compared sleeve patients converted to bypass against sleeve patients who stayed put and added a GLP-1 drug. HbA1c control showed no significant difference between the groups at any time point. On the other hand, the conversion group started with a higher HbA1c (6.19 versus 5.85), which tells you something about who gets sent to surgery. Both groups also reportedly weighed about 242 kilograms at baseline (a figure that looks a lot like a units column having a long day).&lt;&#x2F;p&gt;
&lt;p&gt;A randomized trial, BARI-STEP, enrolled adults at least a year after bypass or sleeve with what it calls “a suboptimal clinical response” and tested semaglutide against placebo. That phrase is clinical language for: the operation did less than everyone hoped. The source list here gives the trial’s design but not its results, so those are not settled in this article.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-a-bypass-might-be-worth-repairing-rather-than-replacing&quot;&gt;Why a bypass might be worth repairing rather than replacing&lt;&#x2F;h2&gt;
&lt;p&gt;This is where TORe’s logic comes from. A bypass, even a stretched one, seems to keep doing something. One report on long-term bypass patients found that even those who regained 100% or more of their lost weight kept type 2 diabetes in remission in about 60% of cases, which the authors read as a weight-independent benefit from bypassing the duodenum. The Oseberg trial, which randomized 109 people with diabetes between 2012 and 2017, found 5-year remission of 63% after bypass versus 30% after sleeve, and total weight loss of 22.2% versus 17.2%. It also found pathological acid reflux more often after the sleeve, while symptomatic low blood sugar after meals was more common after bypass (28% versus 2%).&lt;&#x2F;p&gt;
&lt;p&gt;So picture a surgeon looking at a regained bypass patient and saying, “Look, the plumbing is fine. It’s the faucet.” If the rerouting still earns its metabolic keep, then tightening one hole from the inside is a smaller bet than tearing the whole thing up. That is the pitch, anyway. Whether the tightened hole stays tight is exactly the number this list does not have.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-evidence-does-not-tell-us-yet&quot;&gt;What the evidence does not tell us yet&lt;&#x2F;h2&gt;
&lt;p&gt;The endoscopic procedures have revision rates of their own. In a six-year ESG cohort of 1,377 patients, 5.7% needed revision. ESG’s 12-month total weight loss runs 13% to 16%, according to one review, with outcomes sustained up to 3 years. These are smaller, gentler procedures with smaller, gentler results, which is a reasonable trade, but they are also procedures that sometimes get redone.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a made-up scenario, clearly invented. A patient gets a bypass at 40. The outlet stretches; she gets a TORe at 47. It stretches again; another at 53. By 80 her outlet has been resewn so many times that it has more stitching than a baseball, the endoscopist knows it better than his own kitchen, and the procedure has quietly become a subscription billed every six years. Does anyone want that? Probably not. But nothing in the payment structure obviously stops it either.&lt;&#x2F;p&gt;
&lt;p&gt;For what it is worth, writing about this means reading hundreds of abstracts to report that the most interesting procedure has the least data, which I guess is a job description. The chain runs from a surgeon paid for a first operation, to a riskier second operation, to an endoscopist paid for a sewing job through the mouth, to a drug that might make the sewing unnecessary, and at the end of it nobody planned for the fate of a lot of people to rest on the diameter of one hole.&lt;&#x2F;p&gt;
&lt;p&gt;It is a very small hole, and it matters a lot.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Endoscopic Sleeve Gastroplasty and the MERIT Trial</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/endoscopic-sleeve-gastroplasty/"/>
        <id>https://bariatricalt.com/endoscopic-sleeve-gastroplasty/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/endoscopic-sleeve-gastroplasty/">&lt;p&gt;A doctor can now make a stomach smaller without cutting it open. The doctor goes in through the mouth with a flexible scope and sews the stomach’s own wall into a narrower tube. This is endoscopic sleeve gastroplasty, usually shortened to ESG, and its main evidence is a randomized trial called MERIT, published in The Lancet on July 28, 2022. At 52 weeks, people in MERIT who got ESG had lost a mean 13.6% of their total body weight. People in the control group, who got diet and exercise instead, had lost 0.8%.&lt;&#x2F;p&gt;
&lt;p&gt;On whether it lasts: at 104 weeks, 68% of the ESG patients still being counted had kept off at least 25% of their “excess weight.” A separate review says results held up to 3 years. Past that, the facts available here do not settle anything. The phrase “excess weight” is also doing more work than it looks like, and that is most of what this piece is about.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-endoscopic-sleeve-gastroplasty-actually-does&quot;&gt;What endoscopic sleeve gastroplasty actually does&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the plain version. A gastroenterologist puts a camera down the throat, places stitches in the stomach from the inside, and pulls them tight, so a big stretchy bag becomes a long thin tube. Nothing is removed. A narrative review of ESG describes it as creating a tubular sleeve “without resection, preserving native anatomy.” The whole stomach is still in there. It has just been folded.&lt;&#x2F;p&gt;
&lt;p&gt;Surgical sleeve gastrectomy is different (the site has a separate article on it, and it is the most performed bariatric procedure worldwide). In that operation most of the stomach is cut away and taken out. The surgical version is a demolition. ESG is more like taking in a pair of pants.&lt;&#x2F;p&gt;
&lt;p&gt;So ESG makes the stomach smaller. That is true, but it is not quite the whole story. The more precise and stranger version is that it makes the stomach slower. A MERIT sub-study found that food took much longer to leave the stomach. The half-emptying time was 170.8 minutes at 3 months, against 87.5 for controls, and 133.4 against 87.6 at 12 months. Fasting GLP-1 (the hormone the famous injectable drugs are built to imitate) was up 51% at 12 months, and PYY was up 6.3%. A procedure that looks like tailoring turns out to have some chemistry in it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-the-merit-trial-was-set-up&quot;&gt;How the MERIT trial was set up&lt;&#x2F;h2&gt;
&lt;p&gt;MERIT ran at 9 US centers and enrolled people from December 20, 2017 to June 14, 2019. Participants had to be 21 to 65 years old, with a BMI of 30 to under 40, which covers class 1 and class 2 obesity. Anyone with prior gastrointestinal surgery or inflammatory GI disease was excluded. The average participant was 46, 84% were female, and 33% had diabetes at baseline. Funding came from Apollo Endosurgery and Mayo Clinic (two funders who, one assumes, held no particular views about how the stitches would do).&lt;&#x2F;p&gt;
&lt;p&gt;The trial randomized 209 people in a 1:1.5 ratio: 85 to ESG and 124 to lifestyle modification, meaning a low-calorie diet plus physical activity. Then came a twist at 52 weeks. Controls who had not lost enough weight were offered crossover to ESG. ESG patients were offered “retightening” (a word you more usually hear at a tire shop). Hold onto that one.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-one-year-numbers-say&quot;&gt;What the one-year numbers say&lt;&#x2F;h2&gt;
&lt;p&gt;The primary endpoint needs translating. Take a person’s current weight. Work out what they would weigh at a BMI of 25. Call the gap “excess.” Then ask what fraction of that gap went away. The official name for this is percentage of excess weight loss, or EWL, and it is the number MERIT was built around.&lt;&#x2F;p&gt;
&lt;p&gt;EWL works the way it would if you measured credit card paydown as a share of the balance instead of in dollars. A person with a small balance who pays $500 looks heroic. A person with a large balance who pays the same $500 looks like they are barely trying. Weight works the same way. Someone at a BMI of 32 has much less “excess” than someone at 39, so losing the same number of pounds produces a bigger EWL. None of this is a trick. It is just arithmetic with a starting line drawn at 25.&lt;&#x2F;p&gt;
&lt;p&gt;The results, anyway. At 52 weeks, mean EWL was 49.2% for ESG (standard deviation 32.0, which is a wide spread) and 3.2% for controls. Of the ESG patients, 59 of 77 (77%) cleared the 25% EWL bar, against 13 of 110 (12%) controls. In plainer units, that is the 13.6% versus 0.8% of total body weight from the top.&lt;&#x2F;p&gt;
&lt;p&gt;On health conditions, 41 of 51 ESG patients (80%) improved on at least one metabolic comorbidity and 6 got worse. Among controls, 28 of 62 (45%) improved and 31 (50%) got worse. The trial’s summary does not say which conditions improved. It reports only the “at least one” figure. And a separate analysis of a national surgical registry, called MBSAQIP, found no clinically meaningful comorbidity improvement in ESG patients at 6 months. The two sources disagree. The facts here do not say which one is right.&lt;&#x2F;p&gt;
&lt;p&gt;On safety, ESG-related serious adverse events hit 3 of 131 participants (2%). There were no deaths, no ICU stays, and no one needed surgery. The MERIT paper calls ESG an “intermediate-intensity intervention.” I feel like that is the most honest phrase in the whole literature. For scale, one network meta-analysis put tirzepatide at about 21.3% total weight loss and surgical sleeve at 21.1%. ESG’s 13.6% sits below both, and other articles on the site do that comparison properly.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-obvious-objection-stitches-don-t-last&quot;&gt;The obvious objection: stitches don’t last&lt;&#x2F;h2&gt;
&lt;p&gt;Here is what a sensible person thinks. The stomach is a muscular bag designed to stretch. Putting thread in it sounds temporary. Surely the thread loosens, the bag expands, and in a couple of years the patient is right back where they started. That is not a dumb objection. Stomachs are good at stretching.&lt;&#x2F;p&gt;
&lt;p&gt;MERIT’s answer is that 41 of 60 ESG patients (68%) still had at least 25% EWL at 104 weeks, which it describes as “demonstrating 2-year durability.” On the other hand, look at what that sentence actually measures. Randomized to ESG: 85. Counted at one year: 77. Counted at two years: 60. The bar is 25% of the gap to a BMI of 25. And at the one-year mark, ESG patients could get retightened.&lt;&#x2F;p&gt;
&lt;p&gt;So “durable” turns out to mean something stranger than the objection assumed. It does not mean the stitches held perfectly. It means that, of the people still showing up to be weighed, about two-thirds were at least a quarter of the way down from their starting weight to BMI 25, with a touch-up allowed partway through. It is a bit like a golfer reporting a two-year scoring average with one mulligan built into the rules. That is a perfectly legitimate thing to report, if everyone is told about the mulligan.&lt;&#x2F;p&gt;
&lt;p&gt;You can imagine the follow-up visit (this dialogue is invented): “Okay, we’re putting in a few more stitches, and we’ll see you at the two-year weigh-in.” To be fair, the slower stomach and the higher GLP-1 suggest the effect is not purely mechanical, so a loosened stitch is not necessarily the end of the story. Also to be fair, surgery’s long-run numbers are not tidy either. In the SLEEVEPASS trial, surgical sleeve patients were at 43.5% EWL at 10 years.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-is-still-not-settled&quot;&gt;What is still not settled&lt;&#x2F;h2&gt;
&lt;p&gt;The point is that the clock mostly stops at two years. A review pooling ESG studies reports 13 to 16% total weight loss and 35 to 45% EWL at 12 months, with outcomes “sustained up to 3 years.” Beyond that, the facts here are silent. Among endoscopic options, a network meta-analysis ranked ESG highest for 12-month weight loss, ahead of the Spatz3 and Orbera balloons. Another meta-analysis found ESG had much lower odds of new reflux than surgical sleeve, with an odds ratio of 0.08.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the money. A cost-effectiveness analysis built on MERIT data, taken from the point of view of a US commercial insurer, put ESG at $23,432 per quality-adjusted life year over 5 years. Over longer horizons it found ESG “dominated” lifestyle modification, meaning it came out both cheaper and better. Those longer horizons run past the 104 weeks the trial actually measured, so the model has to assume something about the years in between. That kind of stuff is normal in health economics. It is also exactly where the stitches question lives.&lt;&#x2F;p&gt;
&lt;p&gt;If you are a stomach in the ESG arm and you want to be counted as durable at two years, you had better stay a quarter of the way to BMI 25 and keep coming in to be weighed.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>ESG vs Gastric Sleeve: Smaller Procedure, Smaller Result?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/esg-vs-gastric-sleeve/"/>
        <id>https://bariatricalt.com/esg-vs-gastric-sleeve/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/esg-vs-gastric-sleeve/">&lt;p&gt;There are two ways to turn a human stomach into a narrow tube, and the main difference between them is whether any of the stomach gets thrown away. A laparoscopic sleeve gastrectomy, which a seven-year study of revision operations calls “currently the most performed bariatric procedure worldwide,” cuts part of the stomach out. Endoscopic sleeve gastroplasty, or ESG, goes in through the mouth with a suturing device and stitches the stomach into a tube. A qualitative narrative review of ESG describes this as a way “to create a tubular gastric sleeve without resection, preserving native anatomy.”&lt;&#x2F;p&gt;
&lt;p&gt;On the evidence that exists, the plain answer to esg vs gastric sleeve is that the sleeve takes off more weight and ESG gets people back on their feet faster. A retrospective study of 70 ESG patients and 70 sleeve patients in Lebanon found the sleeve produced greater total body weight loss at both 6 and 12 months. One review puts ESG recovery at 2 to 3 days versus 2 to 6 weeks for the sleeve, and a network meta-analysis found ESG had much lower odds of new reflux (an odds ratio of 0.08). What does not exist, among the studies here, is a large randomized trial putting the two side by side. That is the interesting part.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;esg-vs-gastric-sleeve-what-the-matched-data-shows&quot;&gt;ESG vs gastric sleeve: what the matched data shows&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the comparative evidence, such as it is. The Lebanese study took its ESG patients from Fouad Khoury Hospital and its sleeve patients from Trad Hospital, with procedures done between September 2021 and March 2023. Two hospitals, two groups, one spreadsheet. The sleeve won on weight loss at both time points.&lt;&#x2F;p&gt;
&lt;p&gt;The bigger dataset is the MBSAQIP database. An analysis of its 2023 data covered 115,476 patients, of whom 114,967 had a sleeve and 509 had ESG. That is a lot of sleeves. (Statistically 509 is a perfectly real number; it is just a lonely one.) That analysis found no clinically meaningful improvement in obesity-related conditions among the ESG patients at six months. The MERIT randomized trial, by contrast, reported that 80% of ESG participants improved at least one metabolic comorbidity at 52 weeks.&lt;&#x2F;p&gt;
&lt;p&gt;So which is it? One reading is that ESG does less for the metabolic stuff once it leaves the tidy world of a trial. The other reading is that six months is not 52 weeks, and the people who choose a stitched tube at a surgical center may simply start out different from the people who choose a cut one, with less to fix. The facts here do not say which reading is right.&lt;&#x2F;p&gt;
&lt;p&gt;The long numbers are lopsided too. A review of very long-term outcomes put the sleeve’s weighted mean total weight loss at 24.4% at 10 years. ESG’s best randomized number is from MERIT: 13.6% total body weight loss and 49.2% excess weight loss at 52 weeks, with 68% of participants keeping at least 25% excess weight loss at 104 weeks. But MERIT enrolled people with class 1 and 2 obesity, and a ten-year number against a one-year number is sort of apples against a younger, smaller apple. Smaller procedure, smaller result, probably. How much smaller is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-esg-s-best-trial-was-against-a-diet&quot;&gt;Why ESG’s best trial was against a diet&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the chain of who gets paid for what. Start with an endoscopist who has a procedure that removes nothing. To be taken seriously she needs a randomized trial, and the cleanest one she can run is ESG plus lifestyle changes against lifestyle changes alone, because nobody has to flip a coin over whether to keep part of their stomach. MERIT did basically that, and ESG won easily: 13.6% total body weight loss against 0.8% for the controls.&lt;&#x2F;p&gt;
&lt;p&gt;Next link: the payer. A cost-effectiveness analysis built on MERIT data, from a US commercial payer perspective, found ESG “dominated lifestyle modification alone over longer time horizons” and cost $23,432 per quality-adjusted life year over 5 years. (A quality-adjusted life year is the health economist’s unit of one good year, which is a strange thing to have a unit for, but here we are.) Then a Markov model compared ESG to the drug: semaglutide’s annual cost of about $13,618 would need to fall roughly threefold, to about $3,591, to be cost-competitive with ESG over 5 years for class 2 obesity.&lt;&#x2F;p&gt;
&lt;p&gt;So ESG has been priced against a diet and priced against a drug. Among the facts here, it has not been priced against the sleeve, and neither procedure comes with a dollar figure attached. The invented version of the meeting goes: “Hey guys, it beats the diet by about thirteen points.” “Great. Against the sleeve?” “Different department.”&lt;&#x2F;p&gt;
&lt;p&gt;Look, each party is acting sensibly from where it stands. The endoscopist ran the trial she could actually run. The payer asked the question payers ask, which is whether a thing is worth buying compared to not buying it. The surgeons have 114,967 sleeves a year in one database alone and no special reason to randomize patients away from an operation that works. Also, as in most of medicine, the line between the doctors who study a new procedure, the doctors who teach it, and the doctors who do a great many of them is blurry, in the way the line between a conference and a nice week somewhere warm is blurry.&lt;&#x2F;p&gt;
&lt;p&gt;And so the chain arrives at a place nobody intended. The comparison that patients type into a search box is the one the evidence machine was least built to produce.&lt;&#x2F;p&gt;
&lt;p&gt;This is invented, but consider what the settling trial would need. It needs hundreds of volunteers who are honestly indifferent between losing part of their stomach and keeping all of it, who are equally content with 2 to 3 days of recovery or 2 to 6 weeks, who will let a coin decide, who will come back every year for a decade, and who will not, at any point, look up the other procedure. Such a person exists in roughly the way a frictionless market exists. You would need several hundred of them. They would all need to live near the same two hospitals.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;recovery-days-against-weeks&quot;&gt;Recovery: days against weeks&lt;&#x2F;h2&gt;
&lt;p&gt;This is where the smaller procedure is actually smaller. ESG is usually done under general anesthesia, and one recovery guide lays out the eating plan afterward: clear, non-carbonated liquids and vitamins for days 1 and 2, high-protein, low-calorie full liquids low in fat and sugar for days 3 to 7, then soft and pureed foods for weeks 2 and 3. It’s fine. It is a lot of broth. The headline figure, from a review on the future of restrictive surgery, is 2 to 3 days of recovery for ESG against 2 to 6 weeks for the sleeve.&lt;&#x2F;p&gt;
&lt;p&gt;The stitches are not purely mechanical either. A MERIT sub-study found ESG slowed stomach emptying (a half-time of 170.8 minutes against 87.5 for controls at 3 months, and 133.4 against 87.6 at 12 months) and raised fasting GLP-1 by 51% at 12 months. So the tube does something to the hormones as well as the volume, I guess, which is more than the word “stitches” suggests.&lt;&#x2F;p&gt;
&lt;p&gt;It can also go wrong in its own way. Across 4,350 ESG procedures at six expert centers, 9 patients had abdominal pain lasting more than 15 days, an incidence of 0.21%. The most common suspected cause, in 55.6% of them, was “excessive plication-related tension,” which is in some sense the procedure working slightly too hard. (I am not a gastroenterologist; my qualification here is reading tables with confidence I have not earned.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;revisions-reflux-and-what-happens-later&quot;&gt;Revisions, reflux and what happens later&lt;&#x2F;h2&gt;
&lt;p&gt;In a 6-year cohort of 1,377 ESG patients, 5.7% needed a revision. In the Polish BARI-10-POL study, where 317 of 485 patients had a sleeve, 24.3% of sleeve patients needed a revision over 10 years. Those are different studies with different lengths and different patients, so the gap is suggestive and nothing more. Reflux tilts the same way: the network meta-analysis favored ESG on new reflux, and the Oseberg trial found more acid reflux after the sleeve than after bypass (which is another article’s subject).&lt;&#x2F;p&gt;
&lt;p&gt;There is also a quieter feature of keeping everything. The narrative review notes ESG can serve as a revision for weight regain after earlier non-resective procedures, because the preserved anatomy can be modified safely. A stomach that has not been cut still has all its options.&lt;&#x2F;p&gt;
&lt;p&gt;So: two ways to make a stomach into a tube, and they differ in whether any of it is thrown away and in how carefully anyone has measured the difference. One has a decade of numbers. The other has a trial against a diet and a model against a drug.&lt;&#x2F;p&gt;
&lt;p&gt;So the people choosing between them are the trial.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>The Gastric Balloon: Six Months of Help, Then What?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/gastric-balloon/"/>
        <id>https://bariatricalt.com/gastric-balloon/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/gastric-balloon/">&lt;p&gt;One way medicine treats obesity is to put a balloon in a person’s stomach, leave it there for a while, and then take it out. That is the gastric balloon, more or less: an object that takes up room where dinner would otherwise go, one of the “endoscopic bariatric therapies” that sit somewhere between a prescription and an operation. (The title above says six months, which is the general shape of it. The research mostly measures things “at time of IGB removal,” which is the clinical way of saying the same thing without committing to a calendar.)&lt;&#x2F;p&gt;
&lt;p&gt;Does a gastric balloon work? While it is in, yes. A network meta-analysis of randomized trials found that at the time of balloon removal, all currently available FDA-approved endoscopic bariatric therapies produced “statistically significantly higher percentage total weight loss than control interventions.” After it comes out is the less cheerful part. A narrative review on GLP-1 drugs, surgery and balloons put balloon weight loss at roughly 10 to 15% of total body weight, with typically temporary results after removal. A review titled “Endobariatrics: well past infancy and maturing rapidly” put it more flatly: “Weight loss achieved with intragastric balloons is not sustained long-term after device removal.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-a-gastric-balloon-works-the-dumb-version&quot;&gt;How a gastric balloon works, the dumb version&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the version a reasonably bright ten-year-old could produce. The stomach is a bag. If you put a smaller bag inside the bigger bag, there is less room in the bigger bag. Less room means less food. Less food means less weight. Then you take the smaller bag out, there is room again, and the food (and the weight) come back.&lt;&#x2F;p&gt;
&lt;p&gt;That’s it. That’s the model.&lt;&#x2F;p&gt;
&lt;p&gt;I mean, it is a little unfair to call it dumb, because as far as the evidence in front of me goes, it is basically correct. It makes two predictions: the balloon helps while it is there, and the help fades once it is gone. Both of those predictions turn out to be what the literature says. The dumb version gets there in one paragraph.&lt;&#x2F;p&gt;
&lt;p&gt;The balloon is, structurally speaking, filler. (Filler is a respected term in plenty of fields. It is also what people call the part of a thing they suspect is not doing the real work.) The question the sophisticated version asks is whether the filler does anything beyond filling.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-two-balloons-the-trials-actually-compare&quot;&gt;The two balloons the trials actually compare&lt;&#x2F;h2&gt;
&lt;p&gt;The network meta-analysis compares two balloons, and they are made by two different companies in two different states, which is the kind of detail that research papers include and that I find oddly comforting. The Orbera balloon is made by Apollo Endosurgery, headquartered in Austin, Texas. The Spatz3 is made by Spatz Medical, headquartered in Fort Lauderdale, Florida, and it is described as an “adjustable” gastric balloon.&lt;&#x2F;p&gt;
&lt;p&gt;Adjustable. That is the product’s whole pitch, presumably: a balloon you can tune rather than a balloon you simply have. I don’t know the mechanics of the adjustment from the sources here, and I am not going to make them up. What the sources do tell us is how the two balloons rank against each other, and against endoscopic sleeve gastroplasty (ESG), which is a procedure that reshapes the stomach with stitches instead of filling it with an object. ESG has its own article on this site; here it mostly serves as the yardstick.&lt;&#x2F;p&gt;
&lt;p&gt;You can picture the product meeting. “Hey guys, what if the balloon was adjustable,” says someone, and everyone nods, because who would argue against more control over the thing in a patient’s stomach.&lt;&#x2F;p&gt;
&lt;p&gt;The researchers searched MEDLINE, EMBASE and Cochrane CENTRAL for balloon studies “from inception” and for ESG studies from 2013 until May 2023. “From inception” is a wonderful phrase. It means they went back to the beginning of the balloon. All of it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-network-meta-analysis-found-to-six-decimal-places&quot;&gt;What the network meta-analysis found, to six decimal places&lt;&#x2F;h2&gt;
&lt;p&gt;A network meta-analysis is the sophisticated version. Instead of one trial comparing one thing to a control, it stitches many randomized trials together so that treatments never tested head to head can still be ranked against each other through the shared comparisons. The output includes a P score, which (as far as I can tell from how the paper uses it) is a ranking where higher means more likely to be the best at weight loss.&lt;&#x2F;p&gt;
&lt;p&gt;At the time of removal, the Spatz3 had a P score of 0.822894.&lt;&#x2F;p&gt;
&lt;p&gt;I want to sit with that for a second. Not 0.82. Not “about four-fifths of the way to the top.” Zero point eight two two eight nine four, six decimal places, the precision of a lab scale weighing a grain of salt, applied to the question of how much weight people lost with a balloon in their stomach compared with other people who had a different balloon in theirs. Somewhere a statistician produced the 4 at the end and decided it belonged in the record. That’s fine. It is correct, in the sense that the arithmetic produced it. Whether the sixth decimal place of a weight-loss ranking carries information is, I assume, a question the statistician also had, briefly.&lt;&#x2F;p&gt;
&lt;p&gt;The rest of the table goes like this. ESG had the highest P score at removal (0.889272) and at the 12-month follow-up (0.899469). The Spatz3 scored 0.822894 at removal and 0.842773 at 12 months. The Orbera scored 0.536968 at removal and 0.507165 at 12 months. At the follow-up closest to 12 months, both ESG and the Spatz3 were more effective than the Orbera, “with no statistically significant difference between ESG and Spatz3,” in the network meta-analysis’s words.&lt;&#x2F;p&gt;
&lt;p&gt;That last part is the interesting bit. The adjustable balloon is, statistically, hard to tell apart from the stitched-up stomach at a year. The Orbera ranks lower. Adjustability, whatever it involves, seems to buy something.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happens-to-the-weight-after-the-balloon-comes-out&quot;&gt;What happens to the weight after the balloon comes out&lt;&#x2F;h2&gt;
&lt;p&gt;Now notice what the sophisticated version has not done. It has measured weight loss at removal, and it has measured weight loss at roughly 12 months, and it has ranked balloons against each other at both points to six decimal places. It has not overturned the dumb version’s second prediction. The reviews say it plainly: balloon weight loss is “not sustained long-term after device removal,” and the narrative review calls the results typically temporary.&lt;&#x2F;p&gt;
&lt;p&gt;How much comes back, and how fast, is not settled by the facts in front of me. Nothing here gives a regain curve for balloons the way some drug studies give one. (For contrast, and only for contrast: people in the SURMOUNT-CN extension who stopped tirzepatide regained approximately 9 to 12% of body weight within 6 months but kept about half of the net weight lost. Things that stop being used tend to stop working. This is not a unique property of balloons.)&lt;&#x2F;p&gt;
&lt;p&gt;So here is where the two versions stand. The dumb version: bag in a bag, works while it’s in, stops when it’s out. The sophisticated version: a network meta-analysis of randomized trials across every balloon study since inception, P scores out to the millionths, adjustable versus fixed, ESG as a benchmark, and the conclusion that balloons beat controls while present and do not hold the loss after removal. The longer road has better scenery. Same destination.&lt;&#x2F;p&gt;
&lt;p&gt;Between us, you and I both knew how this was going to end the moment the word “removal” appeared in the outcome measure. Nobody designs a study around “time of removal” for a treatment they expect to keep working after it leaves.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-balloon-sits-next-to-esg-and-everything-else&quot;&gt;Where the balloon sits next to ESG and everything else&lt;&#x2F;h2&gt;
&lt;p&gt;The comparison that matters for this site is not balloon versus balloon but balloon versus the things that stay. A 2022 review characterized ESG as potentially more effective and durable than intragastric balloons, with fewer adverse events than bariatric surgery. In the MERIT trial, ESG produced 13.6% mean total body weight loss at 52 weeks versus 0.8% for controls, and 68% of ESG participants maintained at least 25% excess weight loss at 104 weeks. The narrative review put sleeve gastrectomy at roughly 20 to 30% total body weight loss, “most durable,” and GLP-1 drugs at around 10 to 15%, the same range it gave balloons. Those other comparisons get their own articles here, so I will leave them there.&lt;&#x2F;p&gt;
&lt;p&gt;What this produces is a funny niche. The balloon lands in roughly the same weight-loss range as the drugs while it is in, and its standout version ranks alongside ESG at a year, but its defining feature is that it is designed to leave. Every other treatment on the menu either stays (stitches, surgery) or can be continued (drugs, or whatever). The balloon has an end date built into the product.&lt;&#x2F;p&gt;
&lt;p&gt;This invites an obvious thought experiment, which I am making up entirely and which no source here describes. Suppose the answer to “it stops working when you take it out” were simply “never stop putting one in.” A balloon, then a removal, then another balloon, every few months, forever. A subscription. Balloon-as-a-service. You would want a loyalty program, obviously, and an annual plan at a discount, and eventually some consultant would point out that the customer’s stomach has been continuously occupied for nine years and ask whether this is, functionally, just a permanent device with very frequent maintenance visits. At which point you have reinvented the thing the balloon was supposed to be an alternative to, at the cost of a great many endoscopies. Again, none of that is real. It is just where the logic goes if you follow it far enough without stopping.&lt;&#x2F;p&gt;
&lt;p&gt;The movie “Up” is about a man who ties enough balloons to his house that it floats away, and the whole plot works because the balloons stay tied on. Nobody in the film unties them at the six-month mark and expects the house to keep flying.&lt;&#x2F;p&gt;
&lt;p&gt;I should say that I write explainers about the inside of other people’s stomachs and have no business second-guessing a network meta-analysis, lol, so I will not. The paper is careful and the numbers are what they are. The dumb version and the sophisticated version agree. The sophisticated version just shows its work.&lt;&#x2F;p&gt;
&lt;p&gt;Of all the findings in that network meta-analysis, the one most certain to still hold a year after removal is that Spatz Medical is in Fort Lauderdale and Apollo Endosurgery is in Austin.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Roux-en-Y Gastric Bypass: The Old Standard Still Holding On</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/gastric-bypass/"/>
        <id>https://bariatricalt.com/gastric-bypass/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/gastric-bypass/">&lt;p&gt;Today one of the more reliable ways to end up with a Roux-en-Y gastric bypass is to first get a different operation. The bypass is the older of the two big weight-loss surgeries. It has spent years losing the popularity contest to the gastric sleeve while doing quite well in the head-to-head trials, and it also runs a steady side business as the place sleeve patients go next.&lt;&#x2F;p&gt;
&lt;p&gt;The plain version: the surgeon makes a small pouch out of the top of the stomach and connects it to the small intestine farther down, so food skips most of the stomach and the duodenum (the first stretch of intestine). In the best randomized comparison against the sleeve, the bypass produced more weight loss, more diabetes remission and much less acid reflux. In exchange, patients got more low blood sugar after meals and a gut that now handles food in an unusual order. Whether that trade is worth it depends on who is making it, and the evidence for that is less complete than anyone would like.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-roux-en-y-bypass-is-and-why-it-stopped-being-the-default&quot;&gt;What a Roux-en-Y bypass is, and why it stopped being the default&lt;&#x2F;h2&gt;
&lt;p&gt;The “Y” is literal. Two limbs of intestine meet at a junction, and the result looks, on a diagram, like the letter. Food travels down one arm, digestive juices come down the other, and they meet later than nature planned. It is plumbing, in some sense, and the plumbing is the point.&lt;&#x2F;p&gt;
&lt;p&gt;It used to be the default operation. Now it is not. A seven-year study of revision operations after the sleeve opens with the sentence “Sleeve gastrectomy is currently the most performed bariatric procedure worldwide,” and “performed” is doing a lot of work there. The sleeve is the one with the bookings. The bypass is the one with the reviews.&lt;&#x2F;p&gt;
&lt;p&gt;(I spend my working hours reading confidence intervals for a website, which is a job that sounds better at parties than it is.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-oseberg-trial-says-the-bypass-buys&quot;&gt;What the Oseberg trial says the bypass buys&lt;&#x2F;h2&gt;
&lt;p&gt;The cleanest evidence here comes from the Oseberg trial in Norway. It enrolled 109 people with type 2 diabetes between October 15, 2012, and September 1, 2017, and randomly assigned 54 to gastric bypass and 55 to sleeve gastrectomy. It was triple-blind, which means the patients did not know which operation they got. You can have abdominal surgery and not know which one. Medicine is strange.&lt;&#x2F;p&gt;
&lt;p&gt;At five years, 63% of the bypass group had diabetes remission (an HbA1c under 6.5%), versus 30% of the sleeve group. So the bypass is basically twice as good at diabetes. Actually, no. The trial reports a risk difference of 33.5 percentage points with a confidence interval running from 14.1 to 52.9, which is a more precise and much odder statement: the true advantage could be modest, or it could be more than half the room. It is a big advantage. It is just a blurry one.&lt;&#x2F;p&gt;
&lt;p&gt;The one-year results pointed the same way (a risk ratio of 1.57, p=0.0054, in the intention-to-treat analysis). On weight, the bypass group had lost 22.2% of body weight at five years versus 17.2% for the sleeve. That is a five-point gap, which in a trial table is a small number and on an actual person is a fair amount of person. No one died in either group.&lt;&#x2F;p&gt;
&lt;p&gt;There is also a stranger finding, from a separate long-term study reported through the American College of Surgeons. Bypass patients who regained 100% or more of the weight they had lost still kept their diabetes in remission in about 60% of cases. I mean, that is the operation continuing to work on a problem after appearing to fail at the other one. The researchers read it as a “weight-independent metabolic benefit from duodenal bypass,” which is a formal way of saying the rerouting matters on its own.&lt;&#x2F;p&gt;
&lt;p&gt;There is a meta-analysis of 24 randomized trials and 2,890 participants comparing the two operations on cardiometabolic outcomes. Its headline numbers are not in the material gathered here, so I won’t guess at them.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sleeve-s-customers-and-where-they-end-up&quot;&gt;The sleeve’s customers, and where they end up&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the chain. The sleeve is simpler and has become the most common operation. The sleeve also causes reflux: in Oseberg, pathological acid reflux was more common after the sleeve by 51.1 percentage points. Some sleeve patients reflux, or regain, and need something else. The something else is very often a bypass.&lt;&#x2F;p&gt;
&lt;p&gt;How often? In one German randomized trial of sleeves with and without a band, 20% of standard sleeve patients had been converted to gastric bypass by five years. In a Polish ten-year study, BARI-10-POL, 24.3% of sleeve patients needed a revision. So the bypass’s best-selling product line is, in some sense, fixing the sleeve.&lt;&#x2F;p&gt;
&lt;p&gt;The obvious next move is to make the sleeve fail less. That German trial wrapped a band around some sleeves, and the conversion rate fell to 11.9%. Postprandial regurgitation rose from 23% to 59%. It’s fine. Every fix gets paid for with something.&lt;&#x2F;p&gt;
&lt;p&gt;Then the bypass has its own failures. A Spanish trial protocol comparing bypass with SADI-S puts it bluntly: the bypass is “associated with suboptimal response or recurrent weight gain” in 25% to 50% of cases. So the patients who left the sleeve for the bypass can now leave the bypass for a stronger operation, or for a drug: the BARI-STEP trial enrolled people at least a year after bypass or sleeve with “a suboptimal clinical response” and gave them semaglutide or placebo. Each link in this chain is, I assume, billed by someone, and each is a reasonable answer to the link before it. Laid end to end, they describe a patient who has had two operations and is now in a drug trial.&lt;&#x2F;p&gt;
&lt;p&gt;Someone also looked at the bypass and decided, in the spirit of Beyoncé, that if you liked it you should have put a ring on it. Ring-augmented bypass has been tested in five randomized trials with 920 patients. The ring bought a little more excess weight loss at one, two and three years (about 3 to 4 points), no clear difference at five years in a sample of only 173 patients, roughly three times as much vomiting, and an early signal of more reoperations. Picture the planning meeting (made up, obviously): “Great news, the ring works. Mostly in the vomiting department.” Lol.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-bypass-costs-the-body&quot;&gt;What the bypass costs the body&lt;&#x2F;h2&gt;
&lt;p&gt;The best-measured cost is hypoglycemia. In Oseberg, symptomatic low blood sugar after meals hit 28% of bypass patients versus 2% of sleeve patients. That is the same rerouting that helps diabetes, doing too much of its job at the wrong moment.&lt;&#x2F;p&gt;
&lt;p&gt;Oseberg also counted 10 early complications among 54 bypass patients and late side effects in 17 of 53. The denominator dropped by one between those two figures, and the source does not say why. A separate study of tummy-tuck surgery after massive weight loss found bypass patients had the highest major complication rate, 39.1%, but that was a subgroup of 23 people, which is small enough that I wouldn’t hang much on it.&lt;&#x2F;p&gt;
&lt;p&gt;The long-run vitamin and mineral picture is the part people usually mean by the nutritional consequences of a bypass. The sources gathered for this piece do not put numbers on it, so this piece will not pretend to. That question is not settled here.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;when-the-bypass-beats-the-sleeve-and-what-is-not-settled&quot;&gt;When the bypass beats the sleeve, and what is not settled&lt;&#x2F;h2&gt;
&lt;p&gt;On the randomized evidence collected here, the bypass beats the sleeve on diabetes remission, on weight loss, and quite clearly on reflux. It loses on post-meal hypoglycemia. A newer hybrid, SASI bypass, shows a similar trade against the sleeve in a meta-analysis of 13 studies: better diabetes remission (an odds ratio of 4.20) and better reflux remission, alongside a higher overall complication rate (an odds ratio of 4.39).&lt;&#x2F;p&gt;
&lt;p&gt;What is not settled: one long-term review puts ten-year total weight loss anywhere from 24.4% for the sleeve to about 40% for duodenal switch, but the bypass’s own ten-year figure is not in these facts. Oseberg was a single center with 109 people. How the bypass compares with the newer drugs is a different question, and other articles on this site deal with it. I don’t know who should get which operation, and neither, on these numbers, does anyone else with great precision.&lt;&#x2F;p&gt;
&lt;p&gt;The bypass is no longer the first choice. It is often the second one.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Gastric Sleeve vs Ozempic: Comparing the Numbers Fairly</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/gastric-sleeve-vs-ozempic/"/>
        <id>https://bariatricalt.com/gastric-sleeve-vs-ozempic/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/gastric-sleeve-vs-ozempic/">&lt;p&gt;A network meta-analysis of 23 randomized trials, covering 14,293 people, concluded that a weekly drug and a stomach operation produce almost exactly the same weight loss: a mean 21.3% of total body weight for tirzepatide at 10 or 15 mg, against 21.1% for sleeve gastrectomy. Those are a pharmaceutical product and a surgery, and they finished about two-tenths of a point apart.&lt;&#x2F;p&gt;
&lt;p&gt;If you typed gastric sleeve vs ozempic, that is the closest thing to a straight answer this evidence offers, and it comes with two problems. First, the drug in that comparison is tirzepatide, not the semaglutide sold as Ozempic. The facts here contain no clean head-to-head of the sleeve against semaglutide on weight loss, so that exact question is not settled. Second, “about the same” describes roughly the first year or two. The drug evidence here runs to 72 weeks in trials and three years in one retrospective study. The sleeve has ten-year data, and its numbers move over those ten years.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;gastric-sleeve-vs-ozempic-reading-the-best-sentence-one-clause-at-a-time&quot;&gt;Gastric sleeve vs Ozempic: reading the best sentence one clause at a time&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the sentence, from the meta-analysis titled “Comparison of pharmacotherapies for obesity with sleeve gastrectomy.” It says tirzepatide 10 or 15 mg produced a mean 21.3% total body weight loss, “statistically equivalent to sleeve gastrectomy.” Let’s read it like a contract, because it is about to be treated like one.&lt;&#x2F;p&gt;
&lt;p&gt;“A network meta-analysis.” A network meta-analysis is basically a way of ranking treatments that were not all tested against each other in the same trial, by linking them through the trials that do exist. It is a clever method. It is also a method for comparing people who never met.&lt;&#x2F;p&gt;
&lt;p&gt;“Of 23 randomized controlled trials (14,293 participants).” That is a lot of people. It does not say how many of them had a sleeve and how many took a drug, and drug trials tend to be big while surgical trials tend to be small (the Oseberg surgery trial, for instance, randomized 109 people in total). So the 14,293 is in some sense mostly a drug number, attached to a surgery comparison.&lt;&#x2F;p&gt;
&lt;p&gt;“Tirzepatide 10 or 15 mg.” Not the 5 mg dose, and not Ozempic. The sentence chose its competitor carefully. It’s fine.&lt;&#x2F;p&gt;
&lt;p&gt;“Statistically equivalent.” Here is the jargon. Translated flatly: the researchers could not tell the two apart with the data they had. That is not the same as the two being the same.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-two-tenths-of-a-point-and-the-parentheses-around-it&quot;&gt;The two-tenths of a point, and the parentheses around it&lt;&#x2F;h2&gt;
&lt;p&gt;Look at the gap: 21.3% versus 21.1%. That is 0.2 percentage points. For a made-up patient who weighs 120 kg, two-tenths of a percent of body weight is 240 grams, which is roughly a sandwich. Two entirely different interventions, one involving anesthesia and one involving a pharmacy, landed a sandwich apart. It is a beautiful number.&lt;&#x2F;p&gt;
&lt;p&gt;Then you read the parentheses, which is where the contract keeps its exceptions. The drug’s 95% confidence interval runs from 17.3% to 25.2%. The sleeve’s runs from 14.2% to 28.0%. (I write about this sort of thing for a living and still had to look at those parentheses twice.) The sleeve’s range is nearly 14 points wide. The headline gap is 0.2.&lt;&#x2F;p&gt;
&lt;p&gt;So the honest reading is something like this: the drug is fairly well measured, the sleeve is measured with a garden hose, and the two estimates overlap. You can picture the surgeons at the conference: “Hey, in fairness, our interval is wider than yours.” That is not quite the win it sounds like.&lt;&#x2F;p&gt;
&lt;p&gt;And the sentence has a rival. A 2026 systematic review comparing incretin drugs with surgery said tirzepatide 15 mg “approached but did not match” sleeve gastrectomy weight-loss benchmarks at 72 weeks. Same drug, same operation, a different reading of the same rough terrain. I would rather not think about what the marketing departments have planned for the phrase “statistically equivalent to surgery.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;total-weight-excess-weight-and-other-units-of-loss&quot;&gt;Total weight, excess weight, and other units of loss&lt;&#x2F;h2&gt;
&lt;p&gt;Part of why the sleeve’s range is so wide is that sleeve results really do vary. The Oseberg trial found 17.2% total body weight loss at five years. A German trial of banded versus non-banded sleeves found 27.4% at five years for the standard sleeve. One review puts the sleeve at 25 to 30% total body weight loss at two to five years. Those are all the same operation.&lt;&#x2F;p&gt;
&lt;p&gt;Then there are the units. Some studies report total weight loss, the share of your whole body weight that went away. Others report excess weight loss, the share of the weight above some target that went away. The same review gives the sleeve 60 to 70% excess weight loss and 25 to 30% total. Those describe the same patients (who were presumably not consulted on the choice of denominator).&lt;&#x2F;p&gt;
&lt;p&gt;This is how you end up with headlines where one treatment “loses 60%” and another “loses 21%” and they are basically identical. It is like comparing one quarterback’s completion percentage to another’s yards per game and announcing a winner. Units matter here. They matter a lot.&lt;&#x2F;p&gt;
&lt;p&gt;Drug trials mostly report total weight loss, which is the fairer unit for this comparison. SURMOUNT-1, the big tirzepatide trial, reported 22.5% mean body weight loss at 15 mg, with 36.2% of that group losing at least a quarter of their weight. Put that next to a sleeve’s 60 to 70% excess weight loss and the drug looks small. Put it next to the sleeve’s total weight loss and it looks like a peer.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-long-the-numbers-last&quot;&gt;How long the numbers last&lt;&#x2F;h2&gt;
&lt;p&gt;This is where the comparison stops being symmetrical. At ten years, a long-term review gives a weighted mean of 24.4% total weight loss for the sleeve. The SLEEVEPASS trial found 43.5% excess weight loss for the sleeve at ten years (versus 51.9% for gastric bypass). So the sleeve holds a meaningful amount of its result for a decade, while also slipping.&lt;&#x2F;p&gt;
&lt;p&gt;The slipping has a name. One paper says up to half of sleeve patients may need conversion surgery because of “insufficient weight loss, weight recurrence, or complications.” Weight recurrence is the official phrase. It means the weight came back. A ten-year Polish study found revision procedures in 24.3% of sleeve patients.&lt;&#x2F;p&gt;
&lt;p&gt;For the drugs, the evidence here does not run ten years, so the ten-year comparison is not settled. There is one odd small data point. A prospective study of endometrial cancer patients found that by two years, weight regain occurred in 55.6% of the semaglutide group and 66.7% of the sleeve group, against 14.3% for a structured lifestyle program called DEAR (Diet, Exercise, Accompany and Refresh). The lifestyle program won. That is a small, specific population, and it is one study. But it is a reminder that “durable” is a claim each treatment has to earn separately.&lt;&#x2F;p&gt;
&lt;p&gt;And here is the made-up scenario this all invites. Imagine a patient who decides purely on the 0.2-point gap, picks the drug, then reads the confidence intervals and switches to surgery, then reads the ten-year revision rates and switches back, then reads the DEAR program results and buys running shoes. This patient has now lost zero weight and read four meta-analyses. Lol.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-happens-when-the-sleeve-is-not-enough&quot;&gt;What happens when the sleeve is not enough&lt;&#x2F;h2&gt;
&lt;p&gt;The most direct drug-versus-surgery comparison in these facts is not about first-time patients at all. It is about people who already had a sleeve and did not get the result they wanted. A multicenter retrospective study of 4,901 such patients compared converting the sleeve to gastric bypass (3,004 people) with adding a GLP-1 drug (1,897 people). At three years, conversion produced 26.1% total body weight loss and the drug produced 13.7%.&lt;&#x2F;p&gt;
&lt;p&gt;The two groups started at the same weight: 242.3 kg versus 242.8 kg, with a p-value of 0.993. That is about as “not different” as two groups can be (statisticians rarely get a number this tidy outside a textbook). The study is retrospective, so the patients were not randomly assigned, and people who choose a second operation may differ from people who choose a prescription in ways a weight number does not catch. I don’t know how much that matters. The study cannot fully say either.&lt;&#x2F;p&gt;
&lt;p&gt;So the pattern, as far as these facts go, is roughly this. In the first year or two, the best drug and the sleeve look close, though the two reviews disagree on whether close means equal. Over ten years the sleeve has evidence and the drugs mostly do not. And after a sleeve that underperforms, another operation outdid the drug by about double over three years.&lt;&#x2F;p&gt;
&lt;p&gt;The surgery has a ten-year number and the drug has a 72-week number, and most of the argument is about the years in between.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>The Gastric Sleeve: The World&#x27;s Most Common Weight-Loss Operation</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/gastric-sleeve/"/>
        <id>https://bariatricalt.com/gastric-sleeve/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/gastric-sleeve/">&lt;p&gt;The most common weight-loss operation on Earth is one that a large share of its own patients later have turned into a different operation. The authors of a seven-year study comparing two revision surgeries describe sleeve gastrectomy as “currently the most performed bariatric procedure worldwide,” and the same study says that “up to half of sleeve gastrectomy patients may require conversion surgery due to insufficient weight loss, weight recurrence, or complications.” That is the whole story, really, but it takes a while to explain.&lt;&#x2F;p&gt;
&lt;p&gt;Here is the plain version. A gastric sleeve, or laparoscopic sleeve gastrectomy, reshapes the stomach into a narrow tube by removing part of it (the “ectomy” means what it sounds like). One review puts the sleeve’s weight loss at 25 to 30% of total body weight at two to five years, and a review of very long-term outcomes puts it at 24.4% at ten years. The main trade-off is acid reflux, which in a randomized trial was far more common after a sleeve than after a gastric bypass, and the main competitor on weight is now a drug.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-a-gastric-sleeve-actually-is-and-why-that-is-not-obvious&quot;&gt;What a gastric sleeve actually is, and why that is not obvious&lt;&#x2F;h2&gt;
&lt;p&gt;The sensible reaction to all this is: the stomach is smaller, so you eat less, so you weigh less. That is a perfectly good theory. It fits on an index card. It is also not quite how anyone in the field describes it.&lt;&#x2F;p&gt;
&lt;p&gt;The useful contrast is with endoscopic sleeve gastroplasty, which a narrative review describes as creating “a tubular gastric sleeve without resection, preserving native anatomy” (stitches from the inside, nothing removed). The surgical sleeve gets to roughly the same shape by actually taking stomach out. You would expect two tubes of similar shape to do similar things. They do not: the review of restrictive surgery puts the endoscopic version at 13 to 16% total weight loss at twelve months, against that 25 to 30% for the surgical one.&lt;&#x2F;p&gt;
&lt;p&gt;So shape is not the whole thing. A review in Clinical Diabetology says metabolic improvement after bariatric surgery comes from “both weight loss-dependent effects and surgery-specific mechanisms that are independent of weight loss.” Translated: the operation does something beyond making you eat less, and the something is not fully pinned down. One research group got far enough into the question to build a computational model of a sleeved stomach, called StomachSim, to simulate how food gets digested and emptied. The most popular operation in the world has a physics engine.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-much-weight-the-sleeve-takes-off&quot;&gt;How much weight the sleeve takes off&lt;&#x2F;h2&gt;
&lt;p&gt;Before the numbers, a point of procedure. For the avoidance of doubt, this field reports weight loss in two currencies, and they must not be commingled. “Total weight loss” is the share of your starting weight that is gone. “Excess weight loss” is the share of the weight above some notional target that is gone, which is a bigger-looking number describing the same pounds. A 50% excess weight loss and a 25% total weight loss can be the same patient on the same morning. Readers who compare one to the other do so at their own risk.&lt;&#x2F;p&gt;
&lt;p&gt;With that settled: the long-run sleeve is a mid-20s total weight loss operation. A German randomized trial found 27.4% total weight loss at five years after a standard sleeve, and 31.6% after a “banded” sleeve (one with a ring placed around the tube). The Norwegian Oseberg trial found 17.2% at five years for the sleeve against 22.2% for gastric bypass. The Finnish SLEEVEPASS trial found bypass ahead at ten years too, 51.9% versus 43.5% excess weight loss.&lt;&#x2F;p&gt;
&lt;p&gt;An Italian study of 131 sleeve patients found that men lost more kilograms than women at twelve months (36.6 versus 31.2) but the same percentage of their weight. This is what percentages are for. Bigger people losing bigger absolute amounts is arithmetic, not biology.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-reflux-trade-off-measured&quot;&gt;The reflux trade-off, measured&lt;&#x2F;h2&gt;
&lt;p&gt;The Oseberg trial is the cleanest evidence here, and it is small. It enrolled 109 people with type 2 diabetes between October 15, 2012, and September 1, 2017, put 55 into sleeves and 54 into bypasses, kept it triple-blind, and finished in December 2022. Nobody died in either group.&lt;&#x2F;p&gt;
&lt;p&gt;The headline difference was reflux. Pathological acid reflux, meaning reflux bad enough to show up on testing, was more common after the sleeve by a risk difference of 51.1 percentage points (with a confidence interval running from 28.0 to 74.2, which is wide, but its low end is still large). Bypass, on the other hand, had its own cost: symptomatic low blood sugar after meals in 28% of bypass patients versus 2% of sleeve patients. To be fair to the sleeve, that is a real point in its column.&lt;&#x2F;p&gt;
&lt;p&gt;The same trial found diabetes remission at five years in 63% of bypass patients versus 30% of sleeve patients. (That fight gets its own article on this site.) A meta-analysis of a different hybrid, the single anastomosis sleeve ileal bypass, found it beat the plain sleeve on excess weight loss by 9.61 points. Surgeons keep finding things to bolt onto the sleeve. That is sort of a vote.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-so-many-sleeves-become-something-else&quot;&gt;Why so many sleeves become something else&lt;&#x2F;h2&gt;
&lt;p&gt;A Polish ten-year study, BARI-10-POL, found that 24.3% of sleeve patients needed a revisional procedure over ten years. Adjustable gastric banding, in the same study, needed revision 100% of the time. Against that bar the sleeve looks great.&lt;&#x2F;p&gt;
&lt;p&gt;The Danish BARI-STEP trial enrolled people at least a year after a sleeve or bypass who had “a suboptimal clinical response.” Put flatly, the surgery had not worked as well as everyone wanted. That group is large enough to run trials on, which tells you something about its size.&lt;&#x2F;p&gt;
&lt;p&gt;What happens to them? A multicenter retrospective study looked at 4,901 sleeve patients with insufficient loss or regain: 3,004 converted to bypass, 1,897 added a GLP-1 drug. At three years, conversion bypass got 26.1% total weight loss versus 13.7% for the drug group. Starting weights were statistically indistinguishable (p = 0.993). It is not randomized, though, so who chose what, and why, is not settled. A separate meta-analysis found a duodeno-ileal bypass beat a one-anastomosis bypass as a revision at one year, and a seven-year study found iron deficiency more common after the one-anastomosis version. There is, in other words, a whole menu for the second course.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented scenario, clearly made up. A hospital builds a sleeve clinic on the first floor and a revision clinic on the second. The first-floor surgeon finishes a case and tells the patient, “Great result, see you upstairs in five or so years, maybe.” The second floor does well enough to add a third floor for revisions of revisions. Eventually the elevator is the most profitable piece of medical equipment in the building, and the hospital’s annual report lists it as a procedure.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-drugs-come-in&quot;&gt;Where the drugs come in&lt;&#x2F;h2&gt;
&lt;p&gt;Look, this is the part that changed the conversation. A network meta-analysis of 23 randomized trials covering 14,293 people found tirzepatide at 10 or 15 mg produced 21.3% total weight loss, statistically equivalent to the sleeve’s 21.1%. The sleeve’s confidence interval there runs from 14.2% to 28.0%, which is a lot of room. A 2026 systematic review, on the other hand, said tirzepatide 15 mg “approached but did not match” sleeve benchmarks at 72 weeks. So whether a drug equals the sleeve is not settled. It depends which pile of studies you trust.&lt;&#x2F;p&gt;
&lt;p&gt;The relationship between sleeve and drug has also gotten blurry. Plenty of sleeve patients now also see a GLP-1 on the side, an arrangement the literature politely calls “adjuvant.” Everyone involved seems to know about it. The head-to-head comparison is covered in its own piece on this site, for instance, where the units get the care they need.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;so-why-is-it-the-most-common-one&quot;&gt;So why is it the most common one&lt;&#x2F;h2&gt;
&lt;p&gt;The facts here do not explain the sleeve’s popularity. They establish that it is popular, that bypass beats it on weight and diabetes in trials, that it causes more reflux, and that a quarter to half of patients may need something more later. Why the world settled on it anyway is not answered by any of these studies.&lt;&#x2F;p&gt;
&lt;p&gt;The nearest analogy is the most popular car in a country, which is rarely the fastest or the safest and is usually the one that is good enough at most things. I guess the sleeve is the Camry of surgery. Anyway, if up to half of sleeves become something else, then one of the busier routes to a gastric bypass is to first choose the operation that is specifically not a gastric bypass.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>GLP-1 Drugs After Bariatric Surgery</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/glp-1-after-bariatric-surgery/"/>
        <id>https://bariatricalt.com/glp-1-after-bariatric-surgery/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/glp-1-after-bariatric-surgery/">&lt;p&gt;Here is a small fact about the gastric sleeve: for a lot of people it is the operation, and for a lot of other people it turns out to be the first operation. The sleeve removes most of the stomach, weight comes off, and then over the years some of it comes back, or it never came off as far as anyone hoped. A comprehensive review of very long-term outcomes puts the weighted mean total weight loss 10 years after sleeve gastrectomy at 24.4%, the lowest of the procedures it covered. People who search “ozempic after gastric sleeve” are mostly asking what happens next.&lt;&#x2F;p&gt;
&lt;p&gt;The plain answer is that the drug does something, it does less than a second operation, and the evidence is thinner than you would like. (People say “Ozempic” for the whole GLP-1 class the way they say “Band-Aid,” while the studies say “GLP-1 receptor agonists” and mean several drugs.) The largest comparison available here, a multicenter retrospective study of 4,901 people with a prior sleeve and either insufficient loss or regain, found that at 3 years, converting the sleeve to a gastric bypass produced 26.1% total body weight loss, versus 13.7% for adding a GLP-1 drug. A randomized trial built to measure the drug cleanly after surgery, called BARI-STEP, exists. Its results are not among the facts here. So that part is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-not-just-take-the-drug-and-skip-the-second-surgery&quot;&gt;Why not just take the drug and skip the second surgery&lt;&#x2F;h2&gt;
&lt;p&gt;The sensible reaction goes something like this. A weekly injection is not an operation. If the sleeve underdelivered, you reach for the thing that doesn’t involve a hospital, and you only go back to the operating room if the injection fails too. There is also a slightly more cynical version: wasn’t the surgery supposed to be the thing you did instead of drugs? Now the surgery is the thing you do before drugs?&lt;&#x2F;p&gt;
&lt;p&gt;Both reactions are reasonable. That’s fine. The strange part is the structure underneath them. A sleeve does not leave a person back where they started, with the same options as before. It leaves them as a new category of patient, with a new set of definitions, a new set of trials they qualify for, and a new menu that has both a drug and a sequel operation on it. The decision is less “surgery or drugs” than “which add-on to the surgery you already have.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-anyone-decides-a-sleeve-didn-t-work&quot;&gt;How anyone decides a sleeve didn’t work&lt;&#x2F;h2&gt;
&lt;p&gt;You need a definition of failure before you can study a fix for it, and the field has more than one. A review in Frontiers on endoscopic management says weight recurrence is “an increase of 25% excess weight loss from nadir weight,” which is a measure of how much came back from the lowest point. The BARI-STEP trial uses a different door: its “suboptimal clinical response” is “less than 20% weight loss from surgery,” which is a measure of how far you got in the first place, regardless of what happened after.&lt;&#x2F;p&gt;
&lt;p&gt;These are two different patients. One lost a lot and regained some. The other never lost much. I feel like the literature treats them as one bucket more often than it should, though the large retrospective study above at least names both (“insufficient weight loss or weight recurrence”) in its inclusion criteria.&lt;&#x2F;p&gt;
&lt;p&gt;How big is the bucket? Not small. One study of sleeve conversions says up to half of sleeve patients may eventually need conversion surgery for insufficient loss, regain or complications. The BARI-10-POL study in Poland found revisional procedures in 23.9% of patients over 10 years, including 24.3% after sleeve gastrectomy (and 100% after adjustable gastric banding, which is its own story, told elsewhere on this site). The sleeve is like the first film in a franchise where the studio has already pencilled in a part two, for about a quarter of the audience, maybe half.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-studies-say-about-ozempic-after-gastric-sleeve&quot;&gt;What the studies say about Ozempic after gastric sleeve&lt;&#x2F;h2&gt;
&lt;p&gt;Back to the 4,901 people: 3,004 had the sleeve converted to a Roux-en-Y bypass and 1,897 got a GLP-1 drug on top of the sleeve. After adjusting for sex, baseline BMI, age and non-white race, conversion was associated with 11% greater total body weight loss than the drug.&lt;&#x2F;p&gt;
&lt;p&gt;Now look at 13.7%. That is the drug arm, the supposedly weaker option, and it represents people who already had most of their stomach removed, whose operation had in some sense stopped working, and who then lost another 13.7% of their body weight over three years from a medication. That is not a rounding error. That is a meaningful amount of person, gone, in people whose bodies had already absorbed one large intervention and adapted to it. It loses the comparison by a lot. It is still a strange and impressive number to lose with.&lt;&#x2F;p&gt;
&lt;p&gt;The 11% gap has an obvious reading: the bypass is a more powerful operation than the sleeve, so converting to it does more than adding a drug. That fits the Oseberg randomized trial, which found bypass beat sleeve at 5 years as a first operation, 22.2% versus 17.2% total body weight loss. But this was a retrospective study, so nobody was randomized, and there is a second reading. The people who choose another operation may be different from the people who choose an injection, in ways that sex, BMI, age and race do not capture (motivation, insurance, how badly the sleeve went, whether a surgeon thought they were a good candidate, stuff like that). On that reading, some of the 11% is the operation and some is the selection, and the study cannot tell you the split. Both readings survive the data. Neither wins.&lt;&#x2F;p&gt;
&lt;p&gt;There is also a systematic review finding that adding liraglutide, an older GLP-1 drug, to endoscopic bariatric therapy produced weight loss comparable to the net loss (lowest weight minus regained weight) after surgery alone. Which is a weird benchmark, I suppose, comparing a combination against surgery’s result after regain, but it is the benchmark the review chose. And a focused review on surgery and diabetes summarizes the general state of things with some restraint: GLP-1 drugs may be “alternatives, bridges, or postoperative adjuncts,” though “post-surgical evidence remains limited.” Adjunct is the sexiest word in this literature, in the sense that everyone wants to hook up a drug with an operation and see what the partnership produces.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-drug-before-the-operation-which-is-stranger&quot;&gt;The drug before the operation, which is stranger&lt;&#x2F;h2&gt;
&lt;p&gt;Some people take a GLP-1 before surgery, and one single-center study looked at what that does. Of 216 screened, 193 were analyzed: 111 on a preoperative GLP-1, 82 on nothing. At 12 months, measured from their starting weight, the GLP-1 group was at 34.5% total weight loss versus 29.5%. Seems good for the drug.&lt;&#x2F;p&gt;
&lt;p&gt;Except the GLP-1 group also lost more before the operation (median 9.0 kg versus 5.0 kg). And when you measure from the day of surgery instead, weight, BMI and excess weight loss at 3, 6 and 12 months did not differ between the groups (all p values at least 0.19). The drug’s head start was the whole gap. After the knife, everyone moved at the same speed. The GLP-1 group did have zero major complications out of 111, versus 5 out of 82, which is a real difference in a small retrospective study, or whatever a small retrospective study can establish.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-this-leaves-the-comparison&quot;&gt;Where this leaves the comparison&lt;&#x2F;h2&gt;
&lt;p&gt;Here is a made-up case, clearly invented. A person gets a sleeve, regains, and adds a GLP-1. The drug produces its 13.7%, more or less, and then plateaus, so the person converts to a bypass anyway. Now they are a post-bypass patient with a new nadir, and therefore a new denominator for a new definition of recurrence, and therefore eligible for a new adjunct study. The surgeon says, “Hey, there’s still intestine to work with.” The trial coordinator says, “Great, you’re our ideal enrollee.” At some point the person has been the subject of more studies than the drug has, and each study needs them to have underperformed the previous one to get in the door.&lt;&#x2F;p&gt;
&lt;p&gt;That sounds dumb, but it is basically how the inclusion criteria work, and you and I can both see the incentive: a field that measures interventions against the last intervention will always have a fresh cohort of last interventions to measure against. The point is that the second treatment is now a decision with real numbers on both sides, 26.1% versus 13.7% at three years, with the caveat that nobody has yet randomized people between them.&lt;&#x2F;p&gt;
&lt;p&gt;And since BARI-STEP enrolls only people with less than 20% weight loss from surgery, the sleeve’s most dependable outcome, for a certain slice of patients, is that it makes them eligible for the trial.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Whatever Happened to the Lap-Band?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/lap-band/"/>
        <id>https://bariatricalt.com/lap-band/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/lap-band/">&lt;p&gt;In a Polish study that followed weight-loss surgery patients for ten years, the share of adjustable gastric band patients who needed another operation was 100%. Not most of them. All of them, or at least all of the ones the researchers could still find (which, as we will see, is doing a lot of work).&lt;&#x2F;p&gt;
&lt;p&gt;That is, more or less, what happened to the lap band. It was the gentle option: a ring around the top of the stomach, nothing cut or rerouted, adjustable after the fact and removable if things went badly. The long-term studies say it did much less for diabetes than gastric bypass, and that it came back out, or got turned into some other operation, so often that in one study it happened every single time. Why it fell is partly settled and partly not, and the unsettled part is the interesting part.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-an-adjustable-band-was-supposed-to-work&quot;&gt;How an adjustable band was supposed to work&lt;&#x2F;h2&gt;
&lt;p&gt;The pitch for the band was sort of the pitch for any reversible thing. A gastric bypass rearranges the plumbing, and a sleeve removes most of the stomach (permanently, with no undo button). The band just sat there, a collar around the upper stomach, and a clinician could tighten or loosen it later through a small port. If it didn’t suit you, it came out.&lt;&#x2F;p&gt;
&lt;p&gt;Everyone involved had a sensible reason to like this. A patient facing major surgery was offered something that sounded less final. A surgeon got an operation with less to go wrong on the table. Anyone nervous about permanent anatomy got an off switch. The only open question was whether a collar could do what a rerouting does.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-lap-band-did-for-diabetes-in-numbers&quot;&gt;What the lap band did for diabetes, in numbers&lt;&#x2F;h2&gt;
&lt;p&gt;The cleanest comparison in the evidence comes from the Longitudinal Assessment of Bariatric Surgery, or LABS. After gastric bypass, diabetes remission was 71.2% at one year, 69.4% at three, 64.6% at five and 60.2% at seven. After the band it was 30.7% at one year, 29.3% at three, 29.2% at five and 20.3% at seven.&lt;&#x2F;p&gt;
&lt;p&gt;So the band started at less than half the bypass rate and then lost about a third of that by year seven. (The seven-year confidence interval runs from 9.7% to 30.9%, which is less a measurement than a shrug.) The sources here do not give a band weight-loss figure to set beside the roughly 20% to 30% total body weight loss attributed to the sleeve, so I am not going to invent one.&lt;&#x2F;p&gt;
&lt;p&gt;To be clear, the bypass fades too. A Geisinger study of 2,045 bypass patients found diabetes remission of 54% at three years falling to 38% at fifteen. Fading is the normal condition of this field. The band just faded from a lower starting point, against a competitor that was also fading, and it still lost.&lt;&#x2F;p&gt;
&lt;p&gt;Then there is the Polish study, BARI-10-POL. Its authors reported that “revisional bariatric procedures were required in 23.9% of patients over 10 years, most commonly after sleeve gastrectomy (24.3%) and adjustable gastric banding (100%).” That parenthetical is the most efficient obituary in the bariatric literature.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;there-are-roughly-three-ways-to-read-this&quot;&gt;There are, roughly, three ways to read this&lt;&#x2F;h2&gt;
&lt;p&gt;The band’s decline can be explained three ways, and they get less comfortable as they go. They are not exclusive. You can believe all three at once, and a lot of people in the field sort of do.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;reading-one-it-just-did-less&quot;&gt;Reading one: it just did less&lt;&#x2F;h2&gt;
&lt;p&gt;The first reading is the boring one. The band limited how much food fit in at once, and that was about it. The bypass changes the route food takes, and a study measuring bile acids and gut hormones after bypass found a whole cascade of changes after a meal. The diabetes numbers above look like the difference between doing one thing and doing several. On this reading the band didn’t fail so much as lose a fair fight.&lt;&#x2F;p&gt;
&lt;p&gt;That’s fine as far as it goes. It doesn’t explain the 100%, though. A weaker operation could just stay weaker forever, quietly.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;reading-two-adjustable-means-somebody-keeps-adjusting-it&quot;&gt;Reading two: adjustable means somebody keeps adjusting it&lt;&#x2F;h2&gt;
&lt;p&gt;The second reading is about maintenance. The band’s best feature was that it could be changed after surgery, and a thing that can be changed will be. Every tightening is a visit. Every problem is a decision about whether to keep the device. A ring with an off switch invites the question of when to use the switch.&lt;&#x2F;p&gt;
&lt;p&gt;Think of the cheap home printer, for instance. The printer was never the product; the ink was. An operation that only places a ring, and then needs the ring adjusted, and then needs it removed and replaced with a sleeve or a bypass, has turned one modest operation into two or three. It must be a real hardship for the surgeons who get to perform the second one.&lt;&#x2F;p&gt;
&lt;p&gt;Here is an invented version of the consult. “The nice thing about the band,” a surgeon says, accurately, “is that we can always take it out.” (Invented, but it is the band’s entire sales pitch in one line.) Years later, they take it out.&lt;&#x2F;p&gt;
&lt;p&gt;On the other hand, there is a second way to read the 100% itself. BARI-10-POL had a ten-year follow-up rate of 28.5% (485 of 1,703 patients), and the sources here don’t say how many band patients were among the 485. The people still showing up at a surgical study after a decade are plausibly the people who still have a reason to see a surgeon. A band patient who is doing fine might just not answer the letter. So 100% might mean every band failed, or it might mean every band patient still in touch had a band that failed. The data do not tell those apart.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;reading-three-reversible-means-it-gets-reversed&quot;&gt;Reading three: reversible means it gets reversed&lt;&#x2F;h2&gt;
&lt;p&gt;The third reading matters for everything else on this site. Maybe the band wasn’t a strange failure. Maybe it was the first option honest enough to fail on schedule, because undoing it was the design.&lt;&#x2F;p&gt;
&lt;p&gt;Look at its neighbors. In the same Polish study the sleeve had a 24.3% revision rate. A ten-year meta-analysis found the sleeve carried a markedly higher rate of conversion to bypass than starting with a bypass. In the SLEEVEPASS trial, ten-year reoperation was 15.7% after sleeve and 18.5% after bypass, with no significant difference. Nothing here is a one-time event. Some things are just closer to it.&lt;&#x2F;p&gt;
&lt;p&gt;The balloon is the band’s purest descendant: placed, removed, done. A narrative review titled “GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss” put balloon weight loss at roughly 10% to 15%, with “typically temporary results after removal.” A network meta-analysis of randomized trials found the FDA-approved endoscopic therapies beat control at the moment of balloon removal, which is a precise way of saying they work while they are in. The same review puts GLP-1 drugs at roughly 10% to 15% too, and a drug is the most adjustable device of all (other articles here handle that comparison properly).&lt;&#x2F;p&gt;
&lt;p&gt;And the ring never quite died. Some bypasses are done with a ring added around the pouch. A meta-analysis of randomized trials found overall complications similar to standard bypass, plus a “preliminary signal of higher re-operation rate” with the ring. To be fair, the authors also say the required information size had not been reached, so that one is not settled.&lt;&#x2F;p&gt;
&lt;p&gt;Now push the band’s logic all the way. Imagine (this clinic is entirely made up) a practice where everything is reversible: a band you can loosen, a balloon you can retrieve, a ring you can remove, each one followed by the next. Its revision rate is 100%. Its patient retention is also 100%. Its annual report calls this “lifelong engagement,” and I guess technically it is.&lt;&#x2F;p&gt;
&lt;p&gt;You and I both know how this goes with anything that ships with a cancel button. Anyway, the point is not that reversibility is bad stuff. It is that reversibility was the product, and the product got used.&lt;&#x2F;p&gt;
&lt;p&gt;The band was the operation you could undo. So people undid it.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Duodenal Resurfacing, Liners and the Next Endoscopic Devices</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/newer-endoscopic-devices/"/>
        <id>https://bariatricalt.com/newer-endoscopic-devices/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/newer-endoscopic-devices/">&lt;p&gt;The way the duodenal device business works is that surgeons produce a result they cannot fully explain, and then engineers try to sell the unexplained part separately, without the surgery. Gastric bypass reroutes food past the duodenum (the first stretch of the small intestine), and its diabetes benefits seem to outlast its weight loss. So a lot of clever people have asked whether you could get the duodenum part from the inside, through an endoscope, with no incisions. That family of ideas includes liners, duodenal mucosal resurfacing (DMR), aspiration therapy and a few others.&lt;&#x2F;p&gt;
&lt;p&gt;If you got here by typing endobarrier into a search box, here is the plain answer as far as my sources go. EndoBarrier is the best-known name for the liner idea, and the evidence in front of me does not settle its current status, its regulatory approval or its trial results. I am not going to invent them. (This is a website, not a press release.) What the sources do settle is the reasoning these devices rest on, and the fact that a formal comparison of “all currently available FDA-approved” endoscopic therapies covered balloons and stitched stomachs, not intestinal liners.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-sentence-endobarrier-and-resurfacing-are-built-on&quot;&gt;The sentence EndoBarrier and resurfacing are built on&lt;&#x2F;h2&gt;
&lt;p&gt;Here is the sentence, from the American College of Surgeons’ write-up of a Mayo Clinic study on gastric bypass and diabetes: “Even RYGB patients who regained 100% or more of their surgically-lost weight still maintained T2DM remission in approximately 60% of cases, supporting a weight-independent metabolic benefit from duodenal bypass.”&lt;&#x2F;p&gt;
&lt;p&gt;That is a careful sentence, written by people who knew it would be quoted. I am going to read it like a contract, because that is basically the only skill I have. (My job consists mostly of reading other people’s sentences more slowly than they intended.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;reading-it-one-clause-at-a-time&quot;&gt;Reading it one clause at a time&lt;&#x2F;h2&gt;
&lt;p&gt;“Even.” This word announces that the sentence is about to break an assumption. The normal assumption is that diabetes improves after surgery because the person gets lighter. “Even” tells you the authors found people for whom that link snapped, and the diabetes stayed improved anyway.&lt;&#x2F;p&gt;
&lt;p&gt;“RYGB patients.” Roux-en-Y gastric bypass, specifically. Not sleeve. This matters, because the same Mayo work found that 75% of bypass patients kept remission at five years despite weight regain, versus 34.8% of sleeve patients, with odds of diabetes coming back 5.5 times higher after the sleeve. A sleeve shrinks the stomach and leaves the duodenum in the path of food. A bypass routes food around it. Hold that thought.&lt;&#x2F;p&gt;
&lt;p&gt;“Who regained 100% or more of their surgically-lost weight.” Read literally, this is a group of people who had a major operation to lose weight and then ended up, on the scale, where they started or heavier. I was going to say they got none of the benefit of the surgery. That is wrong, and the precise version is stranger: they got none of the benefit they signed up for, and most of them kept a different benefit that nobody ordered separately.&lt;&#x2F;p&gt;
&lt;p&gt;“Still maintained T2DM remission.” Remission, which is a status that can end, rather than a cure. The sentence does not promise forever. It reports what was true at the time of measurement.&lt;&#x2F;p&gt;
&lt;p&gt;“In approximately 60% of cases.” So about six in ten people whose operation failed by its own headline metric had diabetes that stayed in remission. It is not nothing. It is, to put it gently, a fairly large number to find living inside a group defined by failure.&lt;&#x2F;p&gt;
&lt;p&gt;“Supporting.” Not proving. Observational follow-up of surgical patients can support a theory, and the authors chose the verb that says exactly that much. (Researchers pick verbs the way lawyers do, which is to say expensively.)&lt;&#x2F;p&gt;
&lt;p&gt;“A weight-independent metabolic benefit.” Here is the plain version: when food skips the first part of the intestine, blood sugar seems to behave better, whether or not the person stays thinner. The official name for that is a weight-independent metabolic benefit.&lt;&#x2F;p&gt;
&lt;p&gt;“From duodenal bypass.” This is the clause the device industry reads. Notice it does not say “from gastric bypass.” It assigns the credit to the duodenum. Somewhere an engineer read this and said to a colleague, “Hey, what if we just sold the duodenum part?” It is sort of like hearing a band’s big hit, deciding the drum solo was the good bit, and booking a tour of just the drum solo.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-duodenum-part-looks-like-without-surgery&quot;&gt;What the duodenum part looks like without surgery&lt;&#x2F;h2&gt;
&lt;p&gt;If the benefit comes from food not touching the duodenal wall, there are roughly two endoscopic ways to chase it. You can put something between the food and the wall, which is the liner approach that EndoBarrier is known for. Or you can change the wall itself, which is what “resurfacing” in DMR says it does. Aspiration therapy is a different idea (its name carries more information than my sources do, so I will let the name speak for itself).&lt;&#x2F;p&gt;
&lt;p&gt;To be fair, the logic is reasonable. But notice the gap. The ACS sentence is about a permanent surgical rerouting. A liner or a resurfacing is a guess about which ingredient of that rerouting does the work, and whether a temporary or partial version keeps the effect. The sentence does not say. Neither do my sources.&lt;&#x2F;p&gt;
&lt;p&gt;There is also a selection question the sentence quietly raises. Remission after bypass is not uniform: reviews list shorter diabetes duration, lower baseline HbA1c and preserved beta-cell function as predictors, and remission is associated with not having been on insulin before surgery. For instance, when researchers applied a surgical scoring tool to endoscopic sleeve gastroplasty patients, remission ran 60% in the mild group, 45.5% in the moderate group and 0% in the severe group. So any duodenal device would presumably face the same sorting. Whether it does, for these devices, is not settled by anything I have.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;where-the-endoscopic-options-actually-stand&quot;&gt;Where the endoscopic options actually stand&lt;&#x2F;h2&gt;
&lt;p&gt;Look, here is what the sources do pin down. A network meta-analysis of randomized trials searched MEDLINE, EMBASE and Cochrane CENTRAL for balloon studies from inception and for ESG studies from 2013 until May 2023. It concluded that at the time of balloon removal, “all currently available FDA-approved endoscopic bariatric therapies were associated with statistically significantly higher percentage total weight loss than control interventions.” ESG ranked highest at 12 months (P-score 0.899), ahead of the Spatz3 and Orbera balloons.&lt;&#x2F;p&gt;
&lt;p&gt;Now read that literally too. “All currently available FDA-approved” is a claim about a complete list, and the search terms tell you what the list was: balloons, adjustable balloons, ESG. Liners and resurfacing are not on it. Why not? Maybe they were not approved, maybe not available, maybe they lacked trials that fit the criteria. The sentence does not choose, and I cannot either. It must be a lonely thing, being a device whose most quotable evidence is a sentence about somebody else’s operation.&lt;&#x2F;p&gt;
&lt;p&gt;The things that are on the list have their own articles on this site, so briefly: in the MERIT trial, ESG produced 13.6% total body weight loss at 52 weeks versus 0.8% with lifestyle changes, and balloon weight loss, per one review, “is not sustained long-term after device removal.” A systematic review also found that adding liraglutide to endoscopic therapy matched the net weight loss of surgery, defined as nadir minus regained weight (a comparison that politely subtracts surgery’s worst years before keeping score).&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-duodenum-story-keeps-pointing-back-to-surgery&quot;&gt;Why the duodenum story keeps pointing back to surgery&lt;&#x2F;h2&gt;
&lt;p&gt;The strongest evidence for the duodenum theory comes from comparing operations with each other, not from devices. In the Oseberg randomized trial, gastric bypass reached 63% diabetes remission at five years versus 30% for sleeve gastrectomy. Other work found bypass and duodenal switch carried lower risks of diabetes recurrence than the sleeve. Both of the winners reroute food around the duodenum. The sleeve does not.&lt;&#x2F;p&gt;
&lt;p&gt;That is the whole pitch for the next generation of endoscopic devices, I guess: take the clause “from duodenal bypass,” and try to deliver it without the bypass. It is an elegant sort of thing to attempt. Whether it works is a question for trials that do not appear in my sources.&lt;&#x2F;p&gt;
&lt;p&gt;The network meta-analysis that defined the current shelf identified 821 citations, and 8 made it into the quantitative analysis.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Non-Surgical Weight Loss Options That Have Real Trials Behind Them</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/non-surgical-weight-loss/"/>
        <id>https://bariatricalt.com/non-surgical-weight-loss/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/non-surgical-weight-loss/">&lt;p&gt;In the MERIT trial, the people assigned to lifestyle modification lost 0.8% of their body weight in a year. That is not a typo, and it is not a scandal. It is the control group doing its job, which is to stand next to the treatment and make it look tall. The people in the same trial who got an endoscopic sleeve gastroplasty lost 13.6%.&lt;&#x2F;p&gt;
&lt;p&gt;So here is the plain answer. The non surgical weight loss options with randomized trials behind them sort into three tiers. Lifestyle programs produce modest losses, in the neighborhood of the 5% mark that behavioral studies use as their bar for success. Medications produce the biggest numbers in this group: 16.0% for semaglutide in STEP 3 and 22.5% for the top dose of tirzepatide in SURMOUNT-1. Endoscopic procedures sit between the two, with ESG at 13.6% after a year and intragastric balloons a step below it, with results that one review calls typically temporary.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-lifestyle-tier-of-non-surgical-weight-loss-actually-shows&quot;&gt;What the lifestyle tier of non surgical weight loss actually shows&lt;&#x2F;h2&gt;
&lt;p&gt;Lifestyle programs (diet, exercise, coaching, weigh-ins, the whole apparatus) show up in the trials here mostly as the comparison arm. They are rarely the thing being tested (which is an odd career for a treatment). In STEP 3, everybody got intensive behavioral therapy, and the placebo group, which got the therapy plus a dummy injection, lost 5.7% at 68 weeks. In MERIT the lifestyle arm lost 0.8% at 52 weeks.&lt;&#x2F;p&gt;
&lt;p&gt;I feel like the lifestyle arm is the Washington Generals of medicine. It shows up to every game. It plays honestly. It loses on schedule, because losing is the role it was cast in. Somewhere a trial coordinator is saying, very kindly, “So the good news is you’re in the study, and the other news is you’re in the group that gets the pamphlet.”&lt;&#x2F;p&gt;
&lt;p&gt;On its own terms, the lifestyle tier is measured against a small target. A meta-analysis of the WW program used 5% weight loss as its threshold and found that Non-Hispanic Black participants were significantly less likely than Non-Hispanic White participants to reach it at 3, 6 and 12 months. So the bar is 5%, and the bar is not cleared evenly. Why that gap exists is not settled by the facts here.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;medication-the-biggest-trials-and-the-biggest-numbers&quot;&gt;Medication: the biggest trials and the biggest numbers&lt;&#x2F;h2&gt;
&lt;p&gt;The drug tier is where the large, placebo-controlled trials live. In STEP 3, semaglutide 2.4 mg plus behavioral therapy produced 16.0% mean weight loss against 5.7% for placebo plus therapy, from an average starting weight of 105.8 kilograms. The drug’s own contribution is the gap, a bit over ten points, stacked on top of the lifestyle program everyone already had.&lt;&#x2F;p&gt;
&lt;p&gt;In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean weight loss, and 36.2% of people at that dose lost at least a quarter of their body weight. A network meta-analysis of 23 randomized trials covering 14,293 participants put tirzepatide at 10 or 15 mg at 21.3% total weight loss and sleeve gastrectomy at 21.1%, and called them “statistically equivalent.” That is true, and it is worth reading the intervals: the sleeve estimate runs from 14.2% to 28.0%, which is wide enough to park a truck in. Hard to tell apart is not the same as identical. (The sleeve-versus-drug comparison has its own article on this site, which I will not relitigate here.)&lt;&#x2F;p&gt;
&lt;p&gt;Outside trials, things get noisier. A real-world cohort from Türkiye found adjusted weight loss at month 3 of 8.38% for semaglutide and 11.52% for tirzepatide, a real difference. By month 6 the gap had shrunk to 14.40% versus 15.06% and was no longer significant, though the authors note that “only 4 tirzepatide-treated patients had measurements within the month 6 visit window.” Four is a number of patients. It is not a large one (it is, for instance, smaller than most dinner parties).&lt;&#x2F;p&gt;
&lt;h2 id=&quot;endoscopy-stitches-balloons-and-a-unit-problem&quot;&gt;Endoscopy: stitches, balloons and a unit problem&lt;&#x2F;h2&gt;
&lt;p&gt;The endoscopic tier rests mostly on MERIT, a multicenter randomized trial of ESG against lifestyle modification. Its primary endpoint was excess weight loss at 52 weeks, with excess weight defined as “weight above the ideal for a BMI of 25 kg&#x2F;m².” Translated: your excess weight is whatever you weigh minus what you would weigh if you sat exactly at the top of the normal range.&lt;&#x2F;p&gt;
&lt;p&gt;This matters, and I mean that with some ceremony. Let the record reflect that MERIT reports 49.2% excess weight loss and 13.6% total body weight loss, that these two figures describe the same people at the same moment, and that neither is wrong. They are fractions with different denominators. The first number divides by the weight you were supposed to lose; the second divides by all of you.&lt;&#x2F;p&gt;
&lt;p&gt;To be clear, this is invented, but follow it out. Imagine a clinic that decides the ideal BMI is 31 instead of 25. A patient at BMI 32 who loses a few pounds now has 100% excess weight loss. Set the ideal at the patient’s current weight and every patient is cured at intake, with excess weight loss of infinity percent, a result no journal would print and no marketing department would refuse. The real trials use 25, which is the point of writing the definition down.&lt;&#x2F;p&gt;
&lt;p&gt;On durability, MERIT found that 68% of ESG patients kept at least 25% excess weight loss at 104 weeks. The protocol also allowed that control patients who did not lose enough were offered crossover to ESG at 52 weeks, and that “ESG participants were offered retightening,” which in context is a suturing procedure and out of context sounds like an amenity at a discreet spa. A review of the broader literature puts ESG at 13% to 16% total weight loss at 12 months, sustained up to 3 years.&lt;&#x2F;p&gt;
&lt;p&gt;Balloons sit below ESG. A network meta-analysis of randomized trials ranked ESG first for weight loss at 12 months, ahead of the Spatz3 and Orbera balloons. A narrative review summarizing 2023 to 2025 data put balloons at roughly 10% to 15% total weight loss with “typically temporary results after removal.” The balloon gets its own article here, and that phrase is most of it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;three-ways-to-read-the-evidence-tiers&quot;&gt;Three ways to read the evidence tiers&lt;&#x2F;h2&gt;
&lt;p&gt;There are, roughly, three ways to read this ladder.&lt;&#x2F;p&gt;
&lt;p&gt;The first is the obvious one: the tiers rank how well things work. Lifestyle gets you around 5%, balloons maybe 10% to 15%, ESG around 14%, semaglutide 16%, tirzepatide over 20%. Stuff higher on the list removes more weight. Fine. That reading is not dumb, and it is mostly what the numbers say.&lt;&#x2F;p&gt;
&lt;p&gt;The second is that the tiers also rank how well things have been tested, which is a different question. Drug trials enroll thousands of people against placebo, because a drug company with a product to approve has reason to pay for that. ESG has one big randomized trial against a lifestyle arm, reported in a unit that needs a footnote. Lifestyle, on the other hand, gets tested constantly, but usually as somebody else’s baseline. (Much of my job is converting excess weight loss into total weight loss in my head, and I am not good at it.) So part of the ladder is efficacy, and part is the budget for proving efficacy, and the two are tangled.&lt;&#x2F;p&gt;
&lt;p&gt;The third reading is the least comfortable, i suppose. Every number above is attached to a stopwatch: 52 weeks, 68 weeks, 104 weeks. Balloons are explicitly temporary. The same narrative review that gave balloons 10% to 15% gave GLP-1 drugs about the same, around 10% to 15%, well under the 16% and 22.5% from the trials. What happens to non-surgical losses over a decade is not settled by anything here. Weird, then, that the surgery tier has the long data: the LABS study found 28.4% weight loss seven years after bypass, and a Geisinger study found bypass patients holding at 23% between 10 and 20 years out.&lt;&#x2F;p&gt;
&lt;p&gt;Anyway, the point is that the ladder is real, and it is also short. The non-surgical numbers are good. They are also young.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Weight Regain After Bariatric Surgery: How Common, and Why</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/weight-regain-after-bariatric-surgery/"/>
        <id>https://bariatricalt.com/weight-regain-after-bariatric-surgery/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/weight-regain-after-bariatric-surgery/">&lt;p&gt;There is a formula for deciding whether someone who had weight-loss surgery has regained weight, and it involves a percentage of a percentage of a number that is partly hypothetical. The formula is a real one, from a 2022 review in Frontiers in Endocrinology, and it is not the only one. Several of them are in circulation, and each gives a different answer (which is a lot of answers for one bathroom scale).&lt;&#x2F;p&gt;
&lt;p&gt;So here is the plain answer to weight regain after gastric sleeve, as far as the facts allow: it is common, the sleeve is more prone to it than the bypass or the duodenal switch, and the exact rate depends heavily on which definition the study used. Average total weight loss after a sleeve runs about 25 to 30% at two to five years and about 24.4% at ten years. In one Polish ten-year study, 24.3% of sleeve patients needed a revisional operation. Another study says up to half of sleeve patients may eventually need conversion surgery. The causes, per that same review, are “multifactorial.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-counts-as-weight-regain-starting-small&quot;&gt;What counts as weight regain, starting small&lt;&#x2F;h2&gt;
&lt;p&gt;Start with the most reasonable definition possible. A person has surgery, loses weight, and at some point hits their lowest weight, which the literature calls the nadir. Anything above the nadir is regain. Simple.&lt;&#x2F;p&gt;
&lt;p&gt;Here is a patient I am making up. She weighs 300 lb, has a sleeve, gets down to 200, and a couple of years later weighs 210. By the simple definition she has regained weight. The trouble is that a lowest weight is, by construction, the lowest. Nearly every weight recorded after it will be higher (that is what “lowest” means). A definition that catches everyone tells you very little.&lt;&#x2F;p&gt;
&lt;p&gt;So you add a threshold. The Frontiers review defines weight recurrence as “an increase of 25% excess weight loss from nadir weight.” Unpacking that takes a minute. “Excess weight” is the weight above some reference healthy weight. Say, in our made-up case, the reference is 150 lb, so she started with 150 lb of excess. She lost 100 of them. Her regain counts once she has put back 25% of that 100, which is 25 lb. At 210 she is fine. At 225 she has recurrence.&lt;&#x2F;p&gt;
&lt;p&gt;This is like measuring your progress in a grocery line as a fraction of the people who were ahead of you when you arrived, and then measuring any backsliding as a fraction of that progress. It works. It is just two layers removed from “how much do I weigh.”&lt;&#x2F;p&gt;
&lt;h2 id=&quot;escalating-the-definition-until-it-means-whatever-you-want&quot;&gt;Escalating the definition until it means whatever you want&lt;&#x2F;h2&gt;
&lt;p&gt;Now add a second definition from a different study. The BARI-STEP trial, which tested semaglutide in people who had not done well after surgery, defined a “suboptimal clinical response” as less than 20% weight loss from surgery. That is measured from the starting weight, not the nadir. Our made-up patient at 240 lb has lost exactly 20% of her original 300. Under BARI-STEP she is borderline acceptable. Under Frontiers, at 240, she has regained 40 lb, well past her 25-lb threshold. She is a recurrence and not a failure at the same time.&lt;&#x2F;p&gt;
&lt;p&gt;Keep going. Suppose every research group picks its own threshold (15%, 25%, 50% of excess weight loss), its own reference weight, its own starting point, its own follow-up window, etc. At the far end of this road, the regain rate stops being a fact about patients and becomes a fact about the methods section. Pick a strict enough definition and the rate approaches 100%. Pick a loose one and it approaches zero. It is a batting average where each team decides which at-bats count.&lt;&#x2F;p&gt;
&lt;p&gt;How far along that road is the real world? Pretty far. A pouch-resizing study says weight regain affects 10 to 30% of bypass patients, which is a range wide enough to drive a definition through. Diabetes relapse after surgery, a related problem with the same measurement headaches, is reported anywhere from about 10% to over 60%. And I would rather not think about what the people drafting the next consensus definition have planned.&lt;&#x2F;p&gt;
&lt;p&gt;Everyone involved is behaving sensibly, though. Surgeons want a threshold that flags a real problem rather than normal drift. Researchers want a number they can compare across trials, and inherited whatever definition their field already used. Patients want to know whether the scale is telling them something. Those are three different questions, and one formula cannot answer all of them.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-common-is-weight-regain-after-gastric-sleeve-by-the-numbers&quot;&gt;How common is weight regain after gastric sleeve, by the numbers&lt;&#x2F;h2&gt;
&lt;p&gt;With that caveat stamped on everything, here is what the numbers say. A review of laparoscopic sleeve outcomes put total body weight loss at 25 to 30% at two to five years. A review of very long-term results put the sleeve at 24.4% at ten years, the lowest of the operations it compared, against roughly 40% for the duodenal switch. In the Oseberg randomized trial, the sleeve produced 17.2% total weight loss at five years versus 22.2% for gastric bypass.&lt;&#x2F;p&gt;
&lt;p&gt;Then there are revisions. In the BARI-10-POL study from Poland, 23.9% of patients needed a revisional procedure over ten years, including 24.3% of sleeve patients and 100% of adjustable gastric band patients (lol, the band has its own article). A seven-year study of conversions put it more starkly: “Up to half of sleeve gastrectomy patients may require conversion surgery due to insufficient weight loss, weight recurrence, or complications.” Note that this lumps regain together with reflux and other complications, so it is not a pure regain rate.&lt;&#x2F;p&gt;
&lt;p&gt;Small studies give scarier numbers. A prospective study in endometrial cancer patients found weight regain by two years in 66.7% of the sleeve group and 55.6% of the semaglutide group, against 14.3% in a lifestyle program. These were small groups in a specific population, and I don’t know how much to generalize from them. Probably not a lot.&lt;&#x2F;p&gt;
&lt;p&gt;For comparison, the LABS study found that bypass patients regained a mean 3.9% of baseline weight between years three and seven. And the Frontiers review says the duodenal switch is not associated with high rates of regain because its malabsorption makes it “physiologically more complex to regain weight.” The stronger the plumbing change, the less the weight comes back. That pattern holds.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;why-the-weight-comes-back&quot;&gt;Why the weight comes back&lt;&#x2F;h2&gt;
&lt;p&gt;The full Frontiers list of contributors is “genetic, psychological, behavioral, anatomic, and technical factors.” Which is, in some sense, a list of every category of thing that exists. I mean that sympathetically. A sleeve changes a stomach. It does not change a genome, a job, a sleep schedule, or whatever else is going on in a life.&lt;&#x2F;p&gt;
&lt;p&gt;The anatomic and technical items are the ones specific to surgery: how the operation was built and whether it has changed since. The others are the ones that were there before the surgery and presumably still are. Sorting a given patient into those buckets is most of the work.&lt;&#x2F;p&gt;
&lt;p&gt;And the regain matters for health, not just for the scale. The same review says recurrence is associated with the reappearance of weight-related comorbidities. Here the operations split again. Surgery has metabolic effects that are partly independent of weight loss, per a review in Clinical Diabetology, and those effects seem stronger after bypass. A Mayo Clinic study found 75% of bypass patients kept their diabetes in remission at five years despite regain, versus 34.8% after sleeve. In the DIABETCIR trial, remission persisted at ten years in 3 of 12 sleeve patients. Regain after a sleeve tends to bring more back with it.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-an-evaluation-is-actually-sorting-out&quot;&gt;What an evaluation is actually sorting out&lt;&#x2F;h2&gt;
&lt;p&gt;The clinic version of all this sounds something like: “Okay, you’re up 22 lb from your lowest, which by our definition isn’t recurrence yet, but let’s figure out why.” (I invented that, but I assume it is said somewhere every day.) The evaluation is mostly sorting: is this the anatomy, the original technique, or one of the factors the operation never touched? The facts here do not lay out a standard workup, and I won’t pretend they do.&lt;&#x2F;p&gt;
&lt;p&gt;What comes after the sorting is ground the site covers elsewhere, so briefly. In one multicenter study of people with prior sleeves, converting to bypass produced 26.1% total weight loss at three years versus 13.7% with GLP-1 drugs. A meta-analysis found SADI beat one-anastomosis bypass on weight at one year as a revision, and leakage was the most common major complication of that one-anastomosis revision. The ESG review says endoscopic suturing works as a revision after non-resective procedures, which a sleeve, having had most of the stomach removed, is not. And a 2026 review notes significant regain when incretin drugs are stopped, so drugs carry their own version of the problem.&lt;&#x2F;p&gt;
&lt;p&gt;My job, for what it’s worth, mostly consists of reading other people’s denominators (a hobby that does not come up well at parties). It’s fine. The denominators are where the action is.&lt;&#x2F;p&gt;
&lt;p&gt;Which brings us back to the formula. It still runs on a reference weight that is partly hypothetical, a nadir that is by definition the bottom, and a percentage of a percentage. Our made-up patient can be a recurrence and a success on the same day, depending on which paper is open. The definition is negotiable. The weight is not.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>What Is Bariatric Surgery, and How Does It Actually Work?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/what-is-bariatric-surgery/"/>
        <id>https://bariatricalt.com/what-is-bariatric-surgery/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/what-is-bariatric-surgery/">&lt;p&gt;I spent part of this week reading about bile acids, which is not a sentence I expected to write, and it turns out the most interesting thing about weight-loss surgery is how little of it is about the stomach getting smaller. The plain answer to what is bariatric surgery is this. It is a family of operations that change the stomach, the small intestine, or both, so that people with severe obesity lose a large amount of weight and keep much of it off.&lt;&#x2F;p&gt;
&lt;p&gt;The longer answer is that these operations also change how the gut talks to the liver and the pancreas, through hormones, bile acids and gut bacteria, and that much of the metabolic benefit seems to come from that conversation rather than from smaller meals. A review in Clinical Diabetology by Ciesielska and colleagues says the improvement “results from both weight loss-dependent effects and surgery-specific mechanisms that are independent of weight loss.” How the credit splits between those two halves is not settled.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-is-bariatric-surgery-in-its-simplest-version&quot;&gt;What is bariatric surgery in its simplest version&lt;&#x2F;h2&gt;
&lt;p&gt;Start with the reasonable version. Here is an invented surgeon explaining it to an invented patient: “Your stomach holds a lot of food. We’ll make it hold less. You’ll eat less, and you’ll weigh less.” (I made this person up, but I feel like real ones have said something close.) That’s fine. It’s plumbing.&lt;&#x2F;p&gt;
&lt;p&gt;Now escalate one step. Instead of only shrinking the stomach, you also route food past the first stretch of small intestine, so it skips some of the places where it would normally be absorbed. Still plumbing, just more of it. Less goes in, and less of what goes in gets taken up.&lt;&#x2F;p&gt;
&lt;p&gt;One more step. When food arrives lower in the intestine sooner and less digested, the gut releases more of its own hormones (incretins, the family that includes GLP-1) that tell the pancreas to make insulin and tell the brain it has had enough. So now the operation is also, sort of, a drug. It just manufactures the drug inside the patient, on a schedule set by lunch.&lt;&#x2F;p&gt;
&lt;p&gt;One more. The rerouting changes where bile meets food, which changes the bile acids circulating in the blood, and bile acids turn out to be signaling molecules, not just detergent. The gut bacteria shift too. Push this far enough and you reach the absurd endpoint: an operation described as making the stomach smaller that is really an endocrine procedure, where the smaller stomach is mostly packaging. It’s like a home renovation show where the couple knocks out one wall to open up the kitchen and learns the wall was load-bearing and also running the thermostat.&lt;&#x2F;p&gt;
&lt;p&gt;The weird part is how far down that road the literature already is. A focused review on long-term diabetes effects describes the relevant machinery as an intestine, liver and pancreas “axis,” covering adiposity, insulin sensitivity, beta-cell function, incretin hormones, bile acid signaling and gut microbiota. (The intestine and the liver have the sort of relationship that scientists can only describe, delicately, as an axis.) That is six items. A smaller stomach is not on the list.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-procedure-families-from-smaller-stomach-to-longer-detour&quot;&gt;The procedure families, from smaller stomach to longer detour&lt;&#x2F;h2&gt;
&lt;p&gt;The operations line up roughly along that escalation. The sleeve gastrectomy removes much of the stomach and does no rerouting. Roux-en-Y gastric bypass and one-anastomosis gastric bypass make a small stomach and connect it further down the intestine. The duodenal switch (BPD-DS) and SADI-S keep a sleeve-shaped stomach and send food much further along before it meets the digestive juices. (Each of these gets its own article on this site, so I will be brief here, which is hard for me.)&lt;&#x2F;p&gt;
&lt;p&gt;The point is that the longer the detour, the bigger the number. A comprehensive review of very long-term outcomes found that at 10 years, weighted mean total weight loss ranged from 24.4% for the sleeve to approximately 40% for BPD-DS. Those figures pool different patients from different studies, so the ordering is more trustworthy than the decimals. But the ordering is pretty stark.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;hormones-bile-acids-and-the-part-that-is-not-about-portion-size&quot;&gt;Hormones, bile acids and the part that is not about portion size&lt;&#x2F;h2&gt;
&lt;p&gt;You might assume that sending food on a longer detour means bile acids get lost along the way. A study comparing RYGB with SADI-S found something closer to the opposite. One year after surgery, fasting levels of several conjugated bile acids were significantly higher after SADI-S than after RYGB, and a retention test showed no bile acid malabsorption in the SADI-S patients and normal retention in 90.6% of the RYGB patients. So the body keeps its bile acids and runs more of them through the blood. What exactly the extra bile acids are doing for weight and glucose is, on these facts, not settled.&lt;&#x2F;p&gt;
&lt;p&gt;Bile has a less glamorous side, which is gallstones. In a retrospective cohort of 1,163 patients (377 bypass, 786 sleeve) followed for a mean of 34 months, 8.3% developed symptomatic gallstones, with no significant difference between the two operations. Women had about 2.3 times the risk of men.&lt;&#x2F;p&gt;
&lt;p&gt;And patients who were given ursodeoxycholic acid, which is itself a bile acid, had a hazard ratio for gallstones of 0.13, with a 95% confidence interval of 0.01 to 0.99. Look at that upper bound. A hazard ratio of 1 means no effect at all, and this interval stops one hundredth short of it. The data are consistent with the drug cutting the risk by 99%, and also consistent with it cutting the risk by 1%, and the whole thing clears the bar for significance by the width of a rounding error. I find it kind of beautiful. (It is also an association in a retrospective study, which is a different thing from a trial.)&lt;&#x2F;p&gt;
&lt;h2 id=&quot;how-far-the-real-world-has-gotten&quot;&gt;How far the real world has gotten&lt;&#x2F;h2&gt;
&lt;p&gt;If the operation were only about eating less, you would expect diabetes to improve slowly, in step with the scale. That is not quite what the big cohorts show. In one electronic records study of 8,012 bariatric patients operated on between 2013 and 2026, 2,197 had type 2 diabetes beforehand, and 2,056 of them (93.6%) went at least 90 days without any diabetes medication after surgery. A Malaysian cohort of 1,478 patients found 80.9% of diabetic patients had an HbA1c below 6.5% one year out.&lt;&#x2F;p&gt;
&lt;p&gt;Between us, a 90-day medication-free stretch is a lower bar than “cured,” and I suspect the study’s authors agree, because they went on to count what happened next. Before that, though, one line on drugs, since other articles here handle the comparison: a 2026 systematic review found surgery produced diabetes remission in 23% to 70% of patients against 0% with incretin-based drugs, and five-year weight loss of 25% to 32% against 14.9% to 20.9% with semaglutide or tirzepatide. Those drugs imitate one of the hormones the operation turns up. The operation turns up several, plus bile acids, plus the bacteria stuff.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-part-that-wears-off-or-doesn-t&quot;&gt;The part that wears off, or doesn’t&lt;&#x2F;h2&gt;
&lt;p&gt;Here is what happened next. Of the patients who reached that medication-free interval, 882 (42.9%) later went back on diabetes medication, with a median time to restarting of 1.04 years. Bypass patients were less likely to restart than sleeve patients (hazard ratio 0.778). Longer diabetes duration, higher baseline HbA1c and preoperative insulin use all predicted restarting, with insulin use the biggest of the three (hazard ratio 1.627).&lt;&#x2F;p&gt;
&lt;p&gt;There are two ways to read this. One is that the hormonal effect of the operation fades, and the plumbing eventually reasserts itself as merely plumbing. The other is that the operation never repaired the pancreas at all, and simply bought time against a disease that kept going in the background, so the people who relapsed were the ones with the least time left to buy. The Clinical Diabetology review says long-term outcomes “depend largely on disease severity and residual β-cell function,” which fits both readings, I suppose. The facts here do not pick one.&lt;&#x2F;p&gt;
&lt;p&gt;And for 5% to 8% of patients, the first operation does not produce an adequate response, and they go on to revisional surgery. A review in Frontiers notes that revision and conversion are associated with “higher morbidity and mortality compared to the primary surgical intervention.” So the second try costs more than the first, or whatever the surgical version of interest is.&lt;&#x2F;p&gt;
&lt;p&gt;My own expertise in the gut, before this week, consisted of knowing roughly where lunch goes. Having now read about axes and conjugated bile acids, I can report that the operation built around persuading the pancreas works best on people whose pancreas still needs the least persuading.&lt;&#x2F;p&gt;
</content>
        
    </entry>
    <entry xml:lang="en">
        <title>Who Still Does Best With Surgery in the GLP-1 Era?</title>
        <published>2026-11-01T00:00:00+00:00</published>
        <updated>2026-11-01T00:00:00+00:00</updated>
        
        <author>
          <name>
            
              Unknown
            
          </name>
        </author>
        
        <link rel="alternate" type="text/html" href="https://bariatricalt.com/who-still-needs-bariatric-surgery/"/>
        <id>https://bariatricalt.com/who-still-needs-bariatric-surgery/</id>
        
        <content type="html" xml:base="https://bariatricalt.com/who-still-needs-bariatric-surgery/">&lt;p&gt;I spent part of this week reading a 2026 systematic review that put weight-loss surgery and the new incretin drugs (semaglutide, tirzepatide and their relatives) side by side, and surgery won every category. Not narrowly. The review says surgery “demonstrated superiority over incretin-based therapies across all five primary outcome domains,” those being diabetes remission, weight reduction, heart attacks and deaths, fatty liver resolution and quality of life. It is a sweep, the kind of playoff series where the other team’s fans start talking about next season during game two.&lt;&#x2F;p&gt;
&lt;p&gt;So if you came here asking who qualifies for bariatric surgery, the plain answer is that eligibility is set by guidelines from the surgical societies, most recently the joint 2022 criteria from ASMBS and IFSO, which draw the weight and disease lines surgeons work from. The exact cutoffs are not in the sources behind this article, so I am not going to recite numbers I cannot point to. What those sources do answer is the more useful question, which is who does best once they are over the line. That answer depends a lot less on weight than you might guess.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;what-the-rules-for-who-qualifies-for-bariatric-surgery-can-and-can-t-tell-you&quot;&gt;What the rules for who qualifies for bariatric surgery can and can’t tell you&lt;&#x2F;h2&gt;
&lt;p&gt;An eligibility rule is a height bar at an amusement park. It tells you who is allowed on the ride. It does not tell you who will enjoy it, who will throw up, or who will want to go again in four years.&lt;&#x2F;p&gt;
&lt;p&gt;That’s fine. Guidelines are supposed to be blunt. But it means two people who both clear the 2022 line can have very different odds, and the research on those odds is where the drug era actually changes things. Whether the 2022 criteria fully anticipated how good the newer drugs would get is not something these sources settle (the guidelines and the drugs were, roughly, moving at the same time).&lt;&#x2F;p&gt;
&lt;h2 id=&quot;there-are-roughly-three-ways-to-read-the-sweep&quot;&gt;There are, roughly, three ways to read the sweep&lt;&#x2F;h2&gt;
&lt;p&gt;The first reading is the obvious one: surgery is just better. The numbers are not subtle. In that same 2026 review, surgery was associated with a pooled relative risk of major cardiac events of 0.48 compared with GLP-1 drugs (confidence interval 0.33 to 0.72), which means about half the risk. Sustained five-year weight loss was 25 to 32 percent with surgery against 14.9 to 20.9 percent with semaglutide or tirzepatide. A separate review of very long-term outcomes found that at ten years total weight loss ranged from 24.4 percent for the sleeve to about 40 percent for the duodenal switch (the site’s other articles go through each operation).&lt;&#x2F;p&gt;
&lt;p&gt;Then there is diabetes remission, where surgery achieved 23 to 70 percent and the drugs achieved 0 percent. Zero is a weird number. I feel like it deserves a moment.&lt;&#x2F;p&gt;
&lt;p&gt;Here is what remission means, in very plain words: your blood sugar looks like a non-diabetic person’s while you take no diabetes medicine. Doctors call this remission of type 2 diabetes. Notice the second half of that sentence. If the treatment is a diabetes medicine, then a person on it is, presumably, taking diabetes medicine, and so cannot be in remission by construction (that is my reading of the definition, not something the review spells out). The drug could produce perfect blood sugar forever and still score zero. It is a bit like a race where one runner is disqualified for wearing shoes.&lt;&#x2F;p&gt;
&lt;p&gt;None of that makes surgery’s lead fake. The cardiac and weight numbers do not have this problem. It just means one of the five categories is less of a contest than it looks.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-second-reading-the-drugs-are-the-waiting-room&quot;&gt;The second reading: the drugs are the waiting room&lt;&#x2F;h2&gt;
&lt;p&gt;The second reading says the sweep is the wrong frame because the two things are not really competing. A focused review on bariatric surgery and type 2 diabetes describes the drugs as possible “alternatives, bridges, or postoperative adjuncts” to surgery, then adds that “post-surgical evidence remains limited.” Alternatives, bridges, adjuncts. That is three jobs, and only one of them is rival.&lt;&#x2F;p&gt;
&lt;p&gt;The bridge job has some data. A single-center retrospective study screened 216 patients and analyzed 193, of whom 111 took a GLP-1 drug before surgery and 82 did not. The drug group lost more weight before the operation (median 9.0 kg against 5.0 kg) and had fewer major complications afterward (0 of 111 against 5 of 82, which is a small study and a small number of events). Measured from where everyone started, the drug group was ahead at 12 months, 34.5 percent total weight loss against 29.5 percent, and still slightly ahead at final follow-up, 37.8 against 35.1.&lt;&#x2F;p&gt;
&lt;p&gt;But measured from the day of surgery, weight, BMI and excess weight loss at three, six and twelve months did not differ between the groups at all. Diabetes and blood pressure remission at a year were similar too. This is a dinner bill where one friend counts the drinks he had at the bar before everyone sat down. His total is bigger. The dinner was the same dinner.&lt;&#x2F;p&gt;
&lt;p&gt;That is not a criticism of the study, which reports both anchors honestly. It just means the drug moved people forward in the queue rather than making the operation work better. The drug can also come after surgery: a double-blinded trial called BARI-STEP is testing semaglutide 2.4 mg weekly in adults with a disappointing response to surgery, and its results are not in these sources. One systematic review found that adding liraglutide to an endoscopic procedure produced weight loss comparable to surgery’s net weight loss once regain is subtracted, which is a sentence that does a lot of quiet work.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;the-third-reading-surgery-works-best-on-people-who-need-it-least-urgently&quot;&gt;The third reading: surgery works best on people who need it least urgently&lt;&#x2F;h2&gt;
&lt;p&gt;The third reading is the least comfortable, and it comes from asking who the surgical successes actually are.&lt;&#x2F;p&gt;
&lt;p&gt;An electronic-records cohort of 8,012 bariatric patients included 2,197 with type 2 diabetes before surgery. Of those, 2,056 (93.6 percent) got at least 90 days off diabetes medicine afterward, which is great. Then 882 of them, or 42.9 percent, started diabetes medicine again, at a median of about a year. In plain words: your pills went away, and then your pills came back. The researchers call this medication re-initiation following a medication-free interval. The study’s own title states the conclusion: “Baseline Diabetes Severity Is the Dominant Predictor.”&lt;&#x2F;p&gt;
&lt;p&gt;Longer diabetes duration raised the hazard of going back on medicine (1.219 per standard deviation). Using insulin before surgery raised it more (1.627). Gastric bypass did better than the sleeve (hazard ratio 0.778). Reviews of remission point the same direction: younger age, lower starting HbA1c, shorter duration, less treatment and better-preserved insulin-making cells all predict success, for surgery and for the drugs alike. Reported relapse rates after surgery run from about 10 percent to over 60 percent, which is less a range than a shrug.&lt;&#x2F;p&gt;
&lt;p&gt;The same pattern shows up in a smaller endoscopic procedure. A study applied a surgical scoring tool to endoscopic sleeve gastroplasty and found remission in 60 percent of mild cases, 45.5 percent of moderate ones and 0 percent of severe ones. Nothing is wrong with the patients or the surgeons here. Biology just keeps score early.&lt;&#x2F;p&gt;
&lt;p&gt;This produces a dumb-sounding but real conversation, which I am inventing: “Great news, you qualify. Quick question, how long have you had diabetes, and could it have been less?” The best surgical cohorts are, in the methods-section sense, selected, which is a neutral word in a paper and a slightly pointed one anywhere else.&lt;&#x2F;p&gt;
&lt;h2 id=&quot;so-who-still-does-best-with-surgery&quot;&gt;So who still does best with surgery&lt;&#x2F;h2&gt;
&lt;p&gt;Putting the readings together, the evidence here favors surgery most clearly for people with type 2 diabetes, especially earlier in the disease, and for outcomes like cardiac events and long-run weight where the drugs have not caught up in these data. Bypass looks more durable than the sleeve for diabetes. Drugs before surgery seem to change the starting line more than the finish. Whether drugs after surgery rescue the poor responders is not settled, or whatever the polite version of “the trial isn’t back yet” is.&lt;&#x2F;p&gt;
&lt;p&gt;I suppose that leaves the sweep standing, with an asterisk on the remission game and a note that the winning team plays best against opponents who have only just shown up. Taken one step further, the ideal surgical candidate, by the numbers, developed diabetes last Tuesday and is booked for Wednesday.&lt;&#x2F;p&gt;
</content>
        
    </entry>
</feed>
